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ABSTRACT
Individuals w ith schizophrenia are at an increased risk for developing diabetes and 
experience rates of diabetes two to five times higher than the general population. The 
limited number of studies that have been conducted in the area of schizophrenia and 
comorbid diabetes have been inconsistent in demonstrating whether individuals with 
schizophrenia and comorbid diabetes differ significantly in terms of personal factors, 
functional and clinical characteristics, social involvement and service utilization. Nor have 
these studies consistently shown the impact of comorbid schizophrenia and diabetes on 
quality of life. An examination of the various measures that differentiate individuals w ith 
schizophrenia and comorbid diabetes from those w ithout diabetes were explored.
The prevalence of diabetes among persons w ith schizophrenia was 4.75%. Persons 
w ith comorbid diabetes differed on a number of personal factors, functional and clinical 
characteristics, social involvement and service utilization. Of note, individuals with 
comorbid diabetes were more likely to be female, have a BMI in the obese/overweight 
range, were more likely to be married/partnered and more likely to be unemployed. They 
were also more likely to experience cognitive deficits, impaired self-care, fewer positive 
symptoms, a greater number of physical health problems and medical co-morbidities than 
individuals w ithout diabetes. Individuals w ith diabetes were more likely to experience 
more lifetime psychiatric admissions and were admitted for longer periods of time. With 
respect to quality of life, individuals w ith diabetes were more likely to have poor-self rated 
health (0R=1.61), more likely to report having a confidant [1.27) and more likely to be 
unemployed (0R=2.64).
Il l
The low prevalence of diabetes is consistent with under-detection of diabetes 
among individuals w ith schizophrenia and must be investigated and remedied. Addressing 
diabetes before full on-set through lifestyle interventions and pharmacotherapy should be 
further explored. The underlying reasons for the disparities [i.e. poor self-rated health, 
service utilization, reduced self-care abilities) found should be the focus of future research 
to determine methods to reduce the impact of diabetes on individuals w ith schizophrenia.
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Chapter 1: INTRODUCTION AND LITERATURE REVIEW
INTRODUCTION
In 2004, the number of individuals in Canada affected by schizophrenia was 
estimated to be approximately 234,305 (Goeree et al., 2005). This condition most often has 
an onset in early adulthood, and is believe to be the result of a combination of genetic and 
environmental factors (Tsuang, Stone & Faraone, 2001). The effects of schizophrenia have 
been described on a spectrum, from mild to severe symptoms, from single to multiple to 
chronic episodes, and from episodes with few lasting effects to those that impact across the 
lifetime. The majority of affected individuals experience more chronic symptoms that have 
a lasting effect and increase in severity over time (Kendler, Neale & Walsh, 1995; Goeree et 
al., 2005), including impaired functioning, social dysfunction, and financial and vocational 
problems (Hirsch & Weinberger, 2003). Though some individuals may experience periods 
of remission between episodes, many do not (Dunayevich, Sethuramen, Enerson, Taylor & 
Lin, 2006).
People w ith schizophrenia are affected by a number of comorbid diseases at higher 
rates than the general population (Carney, Jones & Woolson, 2006). Of particular interest 
is type 2 diabetes, which has been shown to be two to five times higher among persons 
w ith schizophrenia (Dixon et al., 2000; Suvisaari et al., 2007). Although the cause for this 
remains unclear, there has been a significant increase in research in the area, in particular 
since the introduction of second generation or atypical antipsychotics (which have been 
implicated in the increased risk of developing diabetes) (Citrome, jaffe, Levine, Allingham 
& Robinson, 2004; Holt, Bushe & Citrome, 2005). In addition, the interaction between a
variety of traditional risk factors (e.g., age, sex, ethnic background and family history of 
diabetes) and increased genetic susceptibility may play a role in the high rate of diabetes 
among persons v/ith schizophrenia. For example, a pathophysiological link between 
schizophrenia, lifestyle (e.g., diet high in saturated fat, increased smoking, and sedentary 
lifestyle) and diabetes is well recognized (Brown, Birtwhistle & Thompson, 1999; Citrome, 
Jaffe, Levine & Martello, 2006; Dixon et al., 2000).
Diabetes among the general population has been shown to impact many domains of 
quality of life and is associated with reduced life expectancy (Gu, Cowie & Harris, 1998). 
Schizophrenia has been termed a ‘life shortening disease' as individuals often live 9-12 
years fewer than the general population (Lambert, Velakoulis & Pantelis, 2003). Few 
studies have examined the interaction between diabetes and schizophrenia and the 
potential impact on quality of life.
The purpose of this study is to better understand the characteristics and needs of 
persons w ith schizophrenia and comorbid diabetes receiving inpatient psychiatric care. 
The personal, functional, clinical and social characteristics, and service utilization of 
persons w ith the comorbid conditions w ill be compared to persons w ith schizophrenia 
only. In addition, the impact of a diagnosis of diabetes on select measures of quality of life 
among persons w ith schizophrenia w ill be explored. It is hoped that the results of this 
study w ill provide a framework whereby persons w ith comorbid schizophrenia and 
diabetes would receive a more holistic plan of support services.
The first section of this literature review w ill focus on the epidemiology and 
prevalence of diabetes in the general population as well as among persons w ith
schizophrenia. The second section w ill describe the known characteristics of individuals 
with diabetes, again among both the general population and persons w ith schizophrenia. 
Third, current literature examining quality of life among persons with the comorbid 
conditions w ill be reviewed.
LITERATURE REVIEW
Part 1; Epidemiology and Prevalence of Diabetes 
Overview of Diabetes
The World Health Organization (WHO) has described diabetes as "a condition 
prim arily defined by the level of hyperglycemia giving rise to risk of microvascluar 
damage..." (WHO, 2006a, p.5), though it can also be described as "a failure to maintain a 
stable level of blood glucose in the face of the normal fluctuations of supply and demand" 
(Surridege & Nath, 2001, p.781). There are two primary forms of chronic diabetes, type I 
and type 2, where the pathogenesis of the two forms of diabetes is drastically different. 
There are two common factors related to the origin of type 2 diabetes, including a marked 
reduction in insulin secretion by the R-cells of the pancreas as well as decreased insulin 
action (insulin resistance) by tissues of the body (DeFronzo, 1992). The progression to 
type 2 diabetes in individuals experiencing both insulin resistance and insulin secretion 
deficiencies has recently been confirmed in a cohort of Japanese individuals (Tokuyama, 
Ishizuka, Matsui, Egashira &Kanatsuka, 2008). The onset of type 2 diabetes occurs over the 
course of a number of years, and it is yet unknown the relative contribution of R-cell 
dysfunction and insulin resistance; however, by the time hyperglycemia and frank diabetes 
occurs, both insulin resistance and impaired insulin secretion are present and detectable.
The onset of type 2 diabetes may occur 9-12 years before a diagnosis leading to a 
vast amount of macrovascular and microvascular degeneration and complications over this 
period of time (Harris, Klein, Welborn & Knuiman, 1992]. Macrovascular damage occurs to 
the large blood vessels, such as the heart and aorta, and commonly leads to cardiovascular 
disease such as heart attacks, strokes and insufficient blood flow to the legs (WHO, n.d.]. 
Microvascular damage occurs in the small blood vessels and commonly leads to 
complications including retinopathy (damage to the eyes, including blindness], 
nephropathy (damage to kidneys and renal failure], and neuropathy (damage to nerves 
leading to impotence and foot disorders] (WHO, n.d.]. More recently, Nichols, H illier and 
Brown (2007] found that the progression from impaired fasting glucose (IFG], a 
'prediabetes' state, to diabetes occurs over the course of 3-6 years. Although IFG is 
detectable during this period before full onset, underdiagnosis occurs at phenomenal rates 
due to the lack of overt symptoms of type 2 diabetes, and thus a lack of screening (Botas, 
Delgado, Castano, 2003; Glaser, 1997; Jesudason, Leong, Dunstan & Wittert, 2003].
As current literature suggests that individuals w ith schizophrenia are affected by 
type 2 diabetes at rates two to five times that of the general population and diabetes has 
been demonstrated to negatively impact quality of life in the general population, the focus 
of this review w ill be on type 2 diabetes only. As the remainder of the paper w ill focus 
solely on type 2 diabetes, the term "diabetes" w ill henceforth refer to type 2 diabetes.
Prevalence of Diabetes
The prevalence of diagnosed diabetes in Canada in 1999/2000 was 5.1%, where 
approximately 90% have type 2 diabetes (Health Canada, 2003]. Worldwide prevalence
rates of diabetes in 2000 were approximately 171 million for adults over the age of 20 
(Wild, Roglic, Green, Sicree & King, 2004) and accounted for 5.2% of worldwide mortality 
(Roglic, Unwin, Bennett, Mathers & Toumilehto, 2005). Assuming age specific prevalence 
rates remain stable. Wild et al. (2004) project an estimated 366 million individuals 
worldwide w ill have diagnosed diabetes by the year 2030.
Prevalence rates of diabetes are particularly high in developed countries, w ith 
mortality rates due to diabetes reaching more than 8% in Canada and the US; while in 
developing countries, excess mortality rates are between 2 and 3% (Roglic et al., 2005). 
Type 2 diabetes is differentially expressed in a number of populations, who are considered 
to be at increased risk due to both increased genetic susceptibility as well as environmental 
risk factors. Caucasian individuals experience much lower prevalence rates of diabetes 
compared to individuals of Asian, African-American, Hispanic/Latino or Native American 
ethnicity; each of which are between 1.5 and 2 times more likely to be affected (Brancati, 
Kao, Folsom, Watson, & Szklo, 2000; McNeely & Boyko, 2004). Aside from ethnicity, the 
Canadian Diabetes Association (2003) recognizes individuals w ith schizophrenia and 
polycystic ovary syndrome to be at an increased risk of developing diabetes, regardless of 
the presence of traditional risk factors.
Prevalence of Diabetes among Individuals with Schizophrenia
Since as early as 1879 there has been a recognized increase in glucose abnormalities 
(including diabetes) among individuals w ith schizophrenia (Maudsley, 1879, as cited in 
Krosnick & Wilson, 2005). Sir Henry Maudsley commented in the 'Pathology of the Mind', 
that "[djiabetes is a disease which often shows itself in families in which insanity prevails”
(Maudsley, 1879, as cited in Krosnick & Wilson, 2005, p. 320). Early studies confirmed the 
increased prevalence of diabetes and glucose abnormalities among individuals with 
schizophrenia; however, research methodologies were severely flawed in many cases with 
no use of controls, small samples and the utilization of retrospective data (Bushe & Holt,
2004). The definition of diabetes and schizophrenia were non-standardized and thus 
patient groups were not consistent between studies. The standardized criteria in the 
definition of both diabetes and schizophrenia has allowed for greater consistency between 
studies in recent years (Bushe & Holt, 2004).
Recent studies suggest a prevalence rate of diabetes among persons w ith 
schizophrenia that is between two and five times that of the general population 
(Mukherjee, Decina, Bocola, Saraceni, & Scapicchio, 1996; Dixon et al., 2000; Sernyak,
Leslie, Alarcon, Losonczy & Rosenheck, 2002; Subramaniam, Chong, & Pek, 2003). The 
association between diabetes and schizophrenia has not been fully elucidated (Holt et al.,
2005). The mechanism by which the increased prevalence occurs is multifactorial, w ith a 
mix of both genetic and environmental factors (Bellivier, 2005; Rouillon & Sorbara, 2005). 
Genetic susceptibility has been suggested as more than 30% of individuals w ith diabetes 
and schizophrenia have a family history of diabetes (Mukherjee, Schnur & Reddy, 1989). A 
recent study by Mathur, Law, Megson and Wei (2008) found a gene interaction in 
medicated patients w ith schizophrenia that leads to increased insulin resistance and may 
contribute to the development of diabetes. Environmental factors such as an unhealthy 
lifestyle, including poor diet, increased rates of smoking and little  exercise (Brown et al., 
1999) may also contribute to the increased rates of diabetes. There is a possible increased 
risk in individuals taking antipsychotic medications; however, the literature is inconsistent
as to the specific interaction between antipsychotics and diabetes. Cohen, Dekker, Peen & 
Gispen-de Wied, (2006) found that, irrespective of the type of antipsychotic (typical or 
atypical), individuals w ith schizophrenia were at a significantly increased risk of 
developing diabetes while others have found increased risk associated w ith particular 
types of atypical antipsychotics only (Citrome et al., 2004).
A recent study by Ryan, Collins and Thakore (2003) suggests an independent link 
between diabetes and schizophrenia. They found that a cohort of drug naïve, first episode 
persons w ith schizophrenia had increased insulin resistance and impaired fasting glucose 
tolerance w ith a prevalence of 15% compared to healthy controls that had no insulin 
resistance or impaired fasting glucose tolerance. These results have been replicated in a 
recent study involving a larger number of participants using randomized, double blind, 
controlled prospective methodology (Saddichha, Manjunatha, Ameen, & Akhtar, 2008).
Underdiagnosis of Diabetes among Individuals with Schizophrenia
In spite of a known increase in risk, diabetes often goes undetected among persons 
w ith schizophrenia. In a study conducted by Cohen, Stolk, Grobbee & Gispen-de Wied 
(2006) examining prevalence of diabetes among persons with schizophrenia receiving 
inpatient and outpatient care, 8% had previously known diabetes, while another 6.5% had 
undiagnosed diabetes, giving a total prevalence of 14.5% in the sample. Subramaniam et al. 
(2003) report that in a chart review of patients with schizophrenia in a long-stay facility, 
the prevalence of confirmed diabetes was 4.9%, while active screening revealed an overall 
prevalence rate of 16%. In a study examining the guidelines set by the American Diabetes 
Association for the diagnosis of diabetes in persons with schizophrenia, van Winkel et al.
(2006) found that less than half of the individuals with diabetes were successfully 
identified. Using a more thorough 2-step method proposed by the World Health 
Organization, 96.2% of individuals were successfully diagnosed.
Factors leading to the under recognition of diabetes in this population include a lack 
of knowledge by health care professionals, lack of consistent medical care, and the fact that 
persons w ith schizophrenia are often unable or unwilling to communicate symptoms of 
diabetes (Voruganti et al., 2007; Goldman, 1999).
Part 2: Characteristics of Individuals with Diabetes and Schizophrenia 
Characteristics of Individuals with Diabetes Alone
The vast majority of studies to date have examined demographic and personal 
characteristics of individuals with diabetes. A set o f ‘traditional risk factors', including 
obesity, physical inactivity, unhealthy diet, cigarette smoking, family history of diabetes 
and age, have been recognized by the World Health Organization & International Diabetes 
Federation (2004) and the Canadian Diabetes Association (2003). The impact of these 
common characteristics, or risk factors, present in individuals with diabetes can have 
serious effects on functioning and quality of life. A number of studies have investigated 
characteristics of diabetes beyond the established demographic characteristics and risk 
factors, and include reports of psychosocial and social support.
Glasgow, Ruggiero, Eakin, Dryfoos & Chobanian (1997) conducted a large national 
study of characteristics of individuals w ith diabetes, including demographic, social and 
emotional factors. With a sample of 2,056 participants living in the US, the authors
examined the impact of these characteristics on three measures of quality of life: physical 
functioning, social functioning and mental health. They found that; females reported 
poorer overall quality of life than males; younger individuals reported less impairment in 
physical and social functioning, but greater impairments on mental health measures 
compared to older individuals; persons with lower educational attainment and lower 
income reported poorer health status; persons living alone reported poorer health status 
when compared to individuals living with at least one other person; and those with private 
insurance coverage had greater quality of life compared to persons with Medicare, 
Medicaid or no coverage. Glasgow et al. (1997) found that longer time since diagnosis of 
diabetes was associated with poorer physical and social functioning; and individuals 
reporting more complications, comorbid conditions (other than diabetes) and who had 
been hospitalized in the last year had lower quality of life. In an examination of the impact 
of self-management behaviours on quality of life scores, the authors found that healthier 
diet, more physical exercise and blood glucose testing improved mental health scores. 
Increased physical activity was also related to higher scores on physical and social 
functioning.
Kumari, Head and Marmot (2004) found that lower grades of employment were 
related to increased risk of developing diabetes, even after controlling for the traditional 
risk factors (BMI, smoking, family history of diabetes, ethnicity, exercise). Overweight, 
obesity, and lifestyle factors (e.g., poor diet, decreased physical activity) were associated 
with increased incidence of diabetes; smoking and social support was not found to affect 
diabetes. Tillotson and Smith (1996) found that, post diagnosis, increasing levels of social 
support predicted better diabetes regimen adherence and more favourable outcomes.
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Maddigan, Feeny and Johnson (2005) found that individuals w ith diabetes were at 
increased risk for experiencing greater amounts of medical comorbidities. The number of 
medical comorbidities was significantly associated w ith lower quality of life in individuals 
w ith diabetes. They specifically examined the impact of heart disease, stroke and arthritis 
on quality of life in individuals with diabetes. They found that individuals w ith diabetes 
alone experienced lower quality of life compared to the general population and the 
combination of any of the comorbid conditions further impacted quality of life.
Feyrot et al. (2005) report on the results from an international study, with 
participants in 13 countries worldwide, on psychosocial problems that affect care in 
individuals w ith diabetes. They note the presence of psychological problems (depression, 
anxiety, stress and burnout) in the majority (61-72%) of persons with diabetes, while only 
9-12% of individuals had received treatment for psychological problems over the last 5 
years. The majority of individuals (41%) also report poor psychological well-being.
Depression has been highlighted as a significant issue in individuals w ith diabetes. 
Two meta-analyses examining clinically relevant depression among individuals w ith 
diabetes have been conducted and found that individuals with diabetes were 1.5-2 times as 
likely to experience depression than non-diabetic controls (Anderson, Freedland, Clouse & 
Lustman, 2001; All, Stone, Peters, Davies, & Khunti, 2006). Women w ith diabetes were 
found to experience significantly higher rates of depression (28%) than men (18%) 
(Anderson et al., 2001). Depression is shown to increase rates of morbidity and mortality, 
independent of health status (Wulsin, Vaillant, & Wells, 1999). It is also associated w ith 
overall reduced quality of life, and physical and social functioning (Egede, 2004). The link
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between diabetes and depression is yet unknown. Talbot & Nouwen (2000) suggest that 
depression may in fact be a risk factor in the development of diabetes as depression often 
precedes the development of diabetes by a number of years.
Characteristics of Individuals with Schizophrenia and Comorbid Diabetes
Few studies have focused on the characteristics of individuals with schizophrenia 
and comorbid diabetes. The majority of studies that have been conducted have centered on 
the association between antipsychotics and diabetes (Bushe & Leonard, 2004; Citrome et 
al., 2004; Mackin, Watkinson & Young, 2005; Saddichha et al., 2008), and have been 
methodologically flawed; few have utilized case control methods to determine differences 
between individuals with the comorbid conditions and those with schizophrenia alone.
Of particular interest is a study conducted by Ascher-Svanum, Zhu, Ernst, Fades & 
Jacobson (2007) that examined the clinical and functional characteristics of individuals 
w ith the comorbid conditions and those of persons w ith schizophrenia only. The study, 
conducted over a three-year period, sought to determine whether the course of 
schizophrenia was affected by a diagnosis of diabetes. The study used a prospective 
naturalistic methodology and captured data from 6 locations across the United States, from 
a variety of treatment centers (i.e. community mental health center, university health care 
systems, community and state hospitals, and Department of Veterans Affairs (VA) Health 
Services). The total sample included 594 participants, with 76 individuals (12.8%) 
reporting a diagnosis of diabetes at study enrollment. The number of complications 
differed significantly, with 79 % of participating individuals w ith the comorbid conditions 
reporting at least 1 other comorbid condition, compared to 50% of individuals with
12
schizophrenia only. Only two functional and clinical outcomes differed significantly 
between the 2 groups over the course of 3 years; higher number of contacts w ith (non- 
psychiatrist) physicians and poorer overall health among those with the comorbid 
conditions. No differences were found in use of psychiatric services, severity of depressive 
or psychotic symptoms, quality of life and relationships.
In a large US national study examining data collected by the Schizophrenia Patient 
Outcomes Research Team (PORT) in 1991, Dixon et al. (2000) investigated the prevalence 
and correlates of diabetes in 14,182 persons w ith a diagnosis of schizophrenia. The rate of 
lifetime diabetes was 14.9% in this sample. Unlike the general population, where the 
prevalence of diabetes is higher in men, women were 2.1 times as likely to have diabetes. 
Ethnicity (i.e., African American or 'other'), increased age, lower educational attainment 
and marital status (i.e., ever having been married) were significantly associated w ith 
increased risk of lifetime diabetes. Subramaniam et al. (2003) report a prevalence rate of 
diabetes of 16% in persons with schizophrenia; however, they found no effect of sex, 
ethnicity or other clinical variables on the likelihood of developing diabetes.
Cohen et al. (2006) found that the age of onset of diabetes among a cohort of 
individuals w ith schizophrenia was significantly younger than is seen amongst the general 
population. The rate of previously known diabetes (8%) in individuals in the study, w ith a 
mean age of 41 years, is normally seen in individuals between the ages of 60 to 65 years in 
the general population. This suggests that there may be an early onset or aging effect that 
occurs in individuals w ith schizophrenia.
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Medication adherence to both antipsychotic and hypoglycemic medication was 
measured in a cohort of individuals with schizophrenia and comorbid diabetes. Individuals 
were more likely to be non-adherent to hypoglycemic medication than antipsychotic 
medications (Piette, Heisler, Ganoczy, McCarthy, & Valenstein, 2007); there was only a 
moderate correlation between adherence to antipsychotic and hypoglycemic medications. 
As the principal focus of the study was not to measure differential medication adherence 
between individuals with and without diabetes, no control group (i.e., schizophrenia only) 
was utilized. However, in previous studies, non-adherence with antipsychotic medication 
has been associated with poor overall outcomes and higher risk for hospitalization (Law, 
Soumerai, Ross-Degnan, & Adams, 2008). Similarly, not adhering to diabetic medication has 
been associated with poorer overall outcomes, higher service utilization costs and 
increased rates of depression (Lin, Katon, Von Korff, et al., 2004; Balkrishnan, Rajagopalan, 
Camacho, et al., 2004).
Many studies, including those previously discussed (Ascher-Svanum et al., 2007; 
Dixon et al., 2000), have utilized self-report as a means to identify individuals w ith diabetes 
as screening is a time consuming and expensive process. It has been shown that diabetes 
goes seriously undiagnosed in individuals w ith schizophrenia and thus there may be 
individuals w ith diabetes in non-diabetes groups, resulting in inaccurate findings 
(Voruganti et al., 2007).
Part 3: Quality of Life
Measures of quality of life (QOL) have become increasingly important in aiding care 
planners in developing effective treatment strategies for individuals w ith schizophrenia
14
(Ruggeri et al., 2005). Although there is no standardized definition for QOL as it applies to 
individuals w ith serious mental illness, including individuals with schizophrenia, Lehman 
(1988) proposed quality of life (QOL) indicators be divided into two categories: (1) 
subjective, which measures a person's satisfaction with particular life domains or aspects 
of their well-being; and (2) objective or functional, which are comprised of observations of 
living conditions, functioning in daily living, participation in meaningful activities and 
interpersonal relationships (Hofer et al., 2004). Subjective measures of quality of life are 
commonly measured through self-report measures on life satisfaction (Voruganti, 
Heslegrave, A wad & Seeman, 1998). Positive, negative and depressive symptoms are 
associated with worse outcomes on subjective quality of life, as are certain socio­
demographic factors including gender, age, educational attainment, employment status and 
living conditions (Caron, Mercier, Diaz & Martin, 2005; Narvaez, Twamley, McKibbin, 
Heaton & Patterson, 2008). No standard definition for positive and negative symptoms of 
schizophrenia exists; however, positive symptoms include delusions, hallucinations, and 
disorganized speech, while negative symptoms include flattened affect, alogia and avolition 
(Andreasen, Nopoulos, Schultz & Miller, 1994). Positive symptoms may be indicators of 
schizophrenia and contribute to initial hospitalization while negative symptoms contribute 
to psychosocial morbidity (Andreasen, Nopoulos, Schultz & Miller, 1994). Objective 
measures of quality of life may also be assessed via self-report, but are distinct from 
measures of life satisfaction and typically include measures of social involvement and 
activities, relationships, marital status, employment status, and living situation (Narvaez, 
Twamley, McKibbin, Heaton, & Patterson, 2008). Severity of psychiatric symptoms.
15
cognitive performance and functional capacity are often found to be correlated w ith 
objective measures of quality of life (Hofer et al., 2005; Palmer et al., 2002).
Watson, Clark and Tellegan (1988) proposed the use of positive and negative affect 
as indicators in measuring quality of life and subsequently developed the Positive and 
Negative Affect Schedule (PANAS) based on two, 10 point scales (Positive and Negative 
Affect). The authors found that Positive Affect (PA), or the extent to which a person feels 
enthusiastic, happy and active, was correlated with high self-reported life satisfaction 
whereas Negative Affect (NA) was associated w ith self-reported stress and poor coping 
(Watson, Clark and Tellegan, 1988). The inclusion of scales that incorporate measures of 
positive and negative affect is increasingly common in measuring quality of life among 
individuals w ith schizophrenia (Gaite et al., 2000).
Quality of life in individuals w ith schizophrenia or diabetes is lower when compared 
to the general population. Few measures of quality life have been consistently measured 
between individuals w ith schizophrenia and individuals with diabetes.
Quality of Life in Individuals with Schizophrenia
The quality of life of individuals w ith schizophrenia is impacted through the course 
of the disease itself as well as through many extraneous factors. Major determinants of 
quality of life in schizophrenia have been described as demographics, symptom severity, 
level of psychosocial functioning and the presence of medication side effects (Awad & 
Hogan, 1994). These are briefly described below.
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Demographic Information
Browne et al. (1996) report that increasing age, which is often related to length of 
illness, is inversely related to scores on quality of life (i.e. older adults have poorer QOL 
scores). Although they report that gender was not significantly associated w ith General 
Well Being (GWB) scores, Norman, Malla, McLean, Voruganti, Cortese et al (2000) found 
that women had significantly higher scores on quality of life measures than did men. 
Norman et al. (2000) also report that individuals who were married scored higher on 
quality of life measures than those who were separated/divorced or who were never 
married; and that individuals living on their own or w ith family reported higher quality of 
life than those living in group or boarding homes.
Psychosocial Functioning
Ho et al. (1998) examined two overall measures of psychosocial functioning, levels 
of social adjustment and the Global Assessment Scale (GAS) as well as six other measures of 
psychosocial functioning in a two-year prospective study of persons w ith first episode 
schizophrenia. Nearly 60% of individuals experienced prominent to severe impairment of 
overall social adjustment, and nearly 50% of individuals met criteria for poor outcome 
based on GAS scores. Furthermore, individuals experienced difficulties w ith relationships 
w ith friends, were less likely to be employed, lost motivation to complete daily tasks and no 
longer enjoyed participating in recreational activities. Gainful employment was also 
associated w ith higher life satisfaction and self-esteem. A study conducted by Caron, 
Lecomte, Stip and Renaud (2005) found that levels of social support and quality of life 
measured were significantly related.
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Symptom Severity
In a review of the literature on quality of life and schizophrenia, Pinikahana,
Happen, Hope and Keks (2002) found that both the severity of symptoms and the type of 
symptom, negative, psychotic or disorganized, have been found to impact quality of life. 
Negative symptoms, as compared to positive or psychotic symptoms, are shown to have a 
more severe impact on quality of life (Hofer et al, 2004; Ho et al., 1998). Ho et al (1998) 
examined the relative impact on quality of life based on the presentation of psychotic, 
negative, or disorganized symptoms and found that negative symptoms were significantly 
associated w ith greater impact on quality of life at two-year follow up, with severity of the 
negative symptoms being correlated w ith a more severe impact on quality of life.
Medication Side Effects
Antipsychotics have proven to be effective in managing the symptoms of 
schizophrenia and are recommended as a first line of defense in the treatment of 
schizophrenia (Davis, Chen & Click, 2003; Lehman et al., 2004). Second generation 
antipsychotics have been associated w ith fewer detrimental side effects and increasing 
quality of life over first generation antipsychotics (Awad & Voruganti, 2004). Lima et al. 
(2005) examined differences in quality of life between individuals taking first generation 
antipsychotics and olanzapine, a second generation antipsychotic, and found that patients 
taking olanzapine showed greater improvements in negative symptomatology and general 
psychopathology. However, there remain a number of side effects that significantly impact 
the quality of life of individuals with schizophrenia including; weight gain, metabolic 
abnormalities (insulin resistance, hyperglycemia, type 2 diabetes), and increased risk of
18
cardiovascular disease [Newcomer, 2007]. Antipsychotics have also been associated w ith 
depression, sedation and diminished sexual desire, which are negatively correlated w ith 
quality of life [Hofer et al., 2004].
Weight gain is consistently reported in individuals taking antipsychotics, even over 
a short period of time [Hofer et al., 2004; Henderson, 2007]. Allison, Mackell and 
McDonnell [2003] reported on the first large-scale study examining the association of 
weight gain and quality of life in people w ith schizophrenia. They found that nearly half the 
participants gained weight, w ith 25% of participants gaining a minimum of 10 pounds in 
the six months prior to the study. Greater amounts of weight gain were associated with 
lower quality of life scores, particularly poorer psychological well-being and self-reported 
general health.
The metabolic syndrome [characterized by the presence of three or more of the 
following risk factors: hypertension, dyslipidemia, impaired glucose tolerance, obesity, and 
insulin resistance/hyperinsulinemia] is a group of risk factors that have been identified in 
the development of cardiovascular disease [National Cholesterol Education Program 
Expert Panel, 2002]. Atypical antipsychotics have been shown to increase the risk of 
developing the metabolic syndrome, a condition that often precedes the development of 
type 2 diabetes and cardiovascular disease [Newcomer, 2007; Saddichha et al., 2008]. 
Saddichha et al. [2008] report prevalence rates of the metabolic syndrome up to 5 times 
higher in first episode schizophrenia patients compared to matched, healthy controls. 
Individuals w ith the metabolic syndrome are more likely to report fair or poor quality of
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life, have a higher number of physically unhealthy days, mentally unhealthy days, and 
activity limited days in the 30 days prior to measurement [Ford & Li, 2008).
Quality of Life in Individuals with Diabetes
Improving the quality of life of individuals w ith diabetes has been recognized as a 
major public health initiative [Health Canada, 2002) as people w ith diabetes have a poorer 
quality of life compared to individuals w ithout chronic disease [Rubin & Peyrot, 1999). In 
both the United States and Spain, studies have been conducted to determine trends in 
quality of life [jiménez-Carcia, jiménez-Trujilo, Hernanadez-Barrera,Carrasco-Carrido, 
Lopez, et al, 2008; Centers for Disease Control and Prevention [GDC), 2006). Over the 
course of 10 years, quality of life did not improve in the US or Spain for people w ith type 2 
diabetes; two to three times as many individuals w ith diabetes report fair or poor overall 
quality of life when compared to the general population.
A number of determinants of quality of life have been identified in the literature and 
include: demographic information, psychosocial factors, and complications.
Demographic Information
Several studies have identified associations between demographic variables and 
quality of life in individuals with diabetes. Obesity [Wexler et al, 2006; Koopmanschap, 
2002), older age [Wexler et al, 2006; Ghanbari, Yekta, Roushan, & Lakeh, 2005; 
Koopmanshap, 2002), smoking [GDC, 2006) and low socioeconomic status [Wexler, 2006) 
is consistently associated w ith lower quality of life. Higher educational attainment has
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been shown to be associated with increased quality of life (CDC, 2006; Jimenez-Garcia et al., 
2008).
The most consistently reported demographic factor associated w ith quality of life 
has been gender. Women with diabetes consistently report poorer quality of life than men 
Qimenez-Garcia et al, 2008; Ghanbari, Yekta, Roushan, & Lakeh, 2005; Koopmanschap, 
2002; Wexler et al, 2006). Goz, Karaoz, Goz, Ekz and Cetn (2005) report that men have self 
perceived higher levels of social support, which is correlated w ith improved quality of life. 
Rubin and Peyrot (1998) found that men reported lower burden of illness and greater 
treatment satisfaction than women.
Psychosocial Functioning
Rubin and Peyrot (1999) indicate that the most significant psychosocial 
determinants of quality of life were whether individuals felt more socially competent, 
received more practical support for diabetes management, and used active coping 
strategies. Higher levels of social support, self-efficacy, better social relations and fewer 
arguments with family were also found to increase quality of life for individuals with 
diabetes (Rubin and Peyrot, 1999).
Wexler et al. (2006) found that other than complications, depression was most 
strongly associated w ith reduced quality of life in persons with diabetes. This is 
particularly disconcerting, as individuals w ith diabetes have been identified as a high-risk 
group for depression (Anderson, Freedland, Clouse & Lustman, 2001). In a review of 
current literature on diabetes and quality of life, Rubin and Peyrot (1999) found that the 
number of complications was associated w ith higher rates of depression and anxiety.
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Social support has been shown to exert a significant effect on quality of life (Goz et 
al., 2007). The presence of greater social support may subsequently improve metabolic 
control, self-management and psychosocial adjustment to diabetes (Goz et al., 2007). Low 
levels of social support are associated w ith poor physical functioning and emotional w ell­
being.
Complications
The most severe impact on quality of life for individuals w ith diabetes is the 
presence of complications (Coffey et al., 2002). Blindness, dialysis, symptomatic 
neuropathy, foot ulcers, amputation, stroke, and congestive heart failure were associated 
w ith more substantial reductions in quality of life (Coffey et al, 2002). Both microvascular 
and macrovascular complications are associated w ith poorer quality of life; however, some 
studies report macrovascular complications are associated w ith even lower scores on 
indices of quality of life (Koopmanschap, 2002; U.K. Prospective Diabetes Study Group,
1999). The presence of both microvascular and macrovascular complications appears to 
compound the effects to reduce quality of life further (Koopmanschap, 2002).
Quality of Life in Individuals with Schizophrenia and Comorbid Diabetes
Quality of life of persons w ith schizophrenia and comorbid diabetes has been 
examined in a lim ited number of studies. Dixon et al. (2000) used a series of questions that 
examined self-rated physical health status, satisfaction with physical health, and overall 
satisfaction w ith life ‘as a whole'. Individuals w ith diabetes that were not being treated 
reported the poorest health status, while persons w ith managed diabetes and those w ith
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lifetime, but no current diabetes, rated health status marginally better. Individuals with 
schizophrenia and no diabetes reported the best physical health status.
Quality of life and physical health status is often associated with the presence of 
physical illnesses. Dixon et al (2000) report that individuals w ith schizophrenia and 
diabetes report a significantly higher number of comorbid conditions than those with 
schizophrenia and no diabetes. The conditions most commonly reported in individuals 
w ith diabetes and schizophrenia are: hypertension, heart problems, seizures, hearing 
problems, and vision problems. Coffey et al. (2002) previously reported that the presence 
of comorbid conditions in individuals w ith diabetes is a significant predictor of poorer 
quality of life.
Study Rationale
Diabetes has been shown to significantly impact quality of life in the general 
population (Glasgow et al., 1997), and its prevalence among persons with schizophrenia is 
two to five times higher than in the general population (Muhkerjee et al., 1996; Dixon et al., 
2000; Sernyak et al., 2002; Subramaniam et al., 2003), though the prevalence is thought to 
be much higher (Cohen et al., 2006). The lim ited number of studies that have been 
conducted in this area have been inconsistent in demonstrating whether individuals w ith 
schizophrenia and comorbid diabetes differ significantly in terms of personal factors, 
functional and clinical characteristics, social involvement and service utilization. Nor have 
these studies consistently shown the impact of comorbid schizophrenia and diabetes on 
quality of life.
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The quality of life of individuals with schizophrenia is already impacted through the 
course of the disease and given that a diagnosis of diabetes may further impact an 
individual's quality of life, further investigation is warranted. An examination of the various 
measures that differentiate individuals w ith schizophrenia and comorbid diabetes from 
those w ithout diabetes may reveal areas in which clinicians could target in developing a 
more holistic plan of care. Determining specific areas that require greater focus in care 
planning may lead to improved quality of life for individuals with the comorbid conditions.
Study Objectives
1. To examine the personal factors, functional and clinical characteristics, social 
involvement and service utilization of individuals with a diagnosis of schizophrenia 
and comorbid diabetes compared to individuals with schizophrenia and no diabetes.
2. To determine the impact of a diagnosis of diabetes on select measures of quality of 




In October 2005, the Ontario Ministry of Health and Long-term Care (MOHLTC] 
mandated the use of the Resident Assessment Instrument -  Mental Health (RAl-MH) for all 
persons admitted to an inpatient psychiatric facility or designated mental health bed in a 
general hospital in Ontario, Canada. At that time, the MOHLTC also mandated the 
submission of all RAl-MH data to the Canadian Institute of Health Information’s [ClHI] 
Ontario Mental Health Reporting System (OMHRS). The current analyses are based on RAl- 
MH admission assessments of all adults aged 18 years or more admitted to an inpatient 
psychiatric facility/bed between October of 2005 and June 2007 (N=39,724).
Access to the OMHRS dataset was provided through a data-sharing agreement 
between the Canadian Institute of Health Information [ClHl] and interiM/. The Lakehead 
University Office of Research has provided ethics approval for secondary analyses of the 
anonymised dataset (REB Project #;016 07-08).
Instrument
interRA/, a not for profit research network, has been instrumental in the creation of 
a number of RAl instruments that are currently being used in Canada and throughout the 
world in long-term , acute, and palliative care as well a num ber of other areas of clinical 
relevance where instruments are currently being developed and implemented [Steel et al., 
2003; Hawes, Fries, James & Guihan, 2007). A consortium of individuals and stakeholders, 
including the JPPC Psychiatric Working Group (PWG) [a group of Ontario based
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researchers) and inter/M / researchers from 5 countries completed development of the 
Resident Assessment Instrument-Mental Health [RAl-MH). The exhaustive process 
included: an extensive literature review; examination of previous RAI instruments as well 
as other applicable assessment instruments; consultations w ith front-line staff including 
psychiatrists, physicians, and nurses; expert working groups; and focus groups [Hirdes et 
al., 2002). The RAI-MH is an instrument designed to support care planning, quality 
improvement, outcome measurement and case-mix based payment systems [Hirdes et al., 
2001).
The RAI-MH instrument was developed in accordance w ith previous RAI 
instruments, but was designed to specifically meet the needs of individuals over the age of 
18 in a variety of psychiatric settings. The instrument is designed to provide a multitude of 
information to providers, stakeholders, researchers and policy developers and has been 
developed to assess function, physical and mental health, social supports and service use 
[Hirdes et al., 2001).
Through previous validity and reliability trials w ith other RAI instruments, criterion 
validity was established for scales embedded w ithin the RAI-MH [Hirdes et al., 2002). 
Inter-rater reliability of the RAI-MH was completed in a trial whereby independent 
assessors, trained in the usage of the assessment instrument, twice evaluated a large 
sample of psychiatric inpatients in a variety of inpatient mental health settings across 
Ontario [Hirdes et al., 2002). Upon completion of the validity and reliability trials, a number 
of items were deleted or modified to increase simplicity and reduce coding complications. 
All items retained for the final version [2.0) of the RAI-MH demonstrate at least acceptable
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levels of inter-rater reliability [k > 0.40), w ith many items demonstrating excellent validity 
w ith kappa values in excess of 0,70 [Hirdes et al., 2002). After the completion of a second 
reliability trial, the instrument was deemed ready for implementation for all inpatient 
psychiatry beds in Ontario beginning in October of 2005 [interRAl).
Clinical staff, trained in the usage of the Resident Assessment Instrument -  Mental 
Health [RAl-MH), assess all individuals in an inpatient psychiatry bed in Ontario w ith in 72 
hours of admission.
Measures
Schizophrenia In the RAl-MH, the psychiatrist or attending physician provides a 
provisional diagnosis upon initial assessment utilizing the RAI-MH. Therefore, a diagnosis 
of schizophrenia was ascertained under the section 'psychiatric diagnostic information' 
w ithin the diagnostic category 'Schizophrenia and other psychotic disorders'. The clinician 
completing the RAI-MH would rank up to three DSM-IV provisional diagnoses contributing 
to the individual's admission. Individuals who had a diagnosis of schizophrenia in any of 
these positions [one, two or three) were considered to have schizophrenia.
Diabetes In the RAl-MH diabetes is coded in the 'Health Conditions and Possible 
Medication Side Effects' section. Clinical assessors are asked to "code for all medical 
diagnoses that are currently subject to active treatment or monitoring" and are directed to 
the person's medical records or ICD-IO-CA manual for the appropriate codes. Medical 
conditions are coded as either primary medical condition or other medical condition.
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Developed by the World Health Organization, the International Statistical 
Classification of Diseases and Related Health Problems [10^^ revision) is a standard used in 
the coding and reporting of clinical diagnoses. The ICD-IO-CA is a version of the coding 
system developed by the Canadian Institute for Health Information [ClHI), in consultation 
w ith a number of high profile physicians and over 100 reviewers, for the classification of 
morbidity tailored to the Canadian population (ClHl, 2001).
Diabetes is coded under the 'Endocrine, Nutritional and Metabolic Diseases’. As 
several versions of the ICD-10 manuals were used throughout the period of data collection, 
all codes for diabetes (E10-E14) were utilized to ascertain a diagnosis of diabetes (ClHI, 
2003; WHO, 2007). Although this may include individuals w ith type 1 diabetes, rates of 
type 1 diabetes are typically below 10%, and even lower among individuals with 
schizophrenia [WHO, 2006a). A diagnosis of diabetes under the primary medical diagnosis 
or other relevant diagnosis categories was considered sufficient to be included in the 
diabetes group.
Personal Characteristics Personal characteristics examined include: age; sex; body mass 
index [BMI); marital status; employment status; economic trade-offs; educational 
attainment; prio r living arrangement and residential status. Data for individuals under the 
age of 18 [n=105) were excluded from data analysis. To facilitate data interpretation, age 
was divided into categories: 18-34 years, 35-64 years and 65 years and older. Body mass 
index [BMI) was calculated by dividing the individuals body weight by the square of their 
height, giving a unit measure of kg/m^ [Brown & Miller, 2006). A number of possible 
outliers were detected through review of the data on height, weight and BMI values.
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Biologically implausible values for weight [less than 501bs.) [n=23) and height [greater 
than 400 or less than 22 centimeters) [n=22) were set as missing. As recommended by the 
World Health Organization [WHO) Expert Committee on Physical Status [1995), cut-off 
values for BMI were set at 4 z-scores below the mean and 5 z-scores above the mean w ith 
extreme values set as missing. BMI was then divided into 4 categories to facilitate 
interpretation: BMI less than 20, between 20 and 25, between 25 and 30, and greater than 
30. M arita l status was combined to form two variables: individuals w ith a partner 
[married, partner/significant other) or no partner [never married, widowed, separated, 
divorced). Employment status was combined into two variables, employed or unemployed, 
w ith current employment status of'other' or 'unknown', as coded in the RAl-MH, set as 
missing. Economic trade-offs, measured over the month prior to admission, include not 
purchasing medications, home heat, necessary health care or adequate food due to lim ited 
funds and was measured as no economic trade-offs in the 30 days prior to admission or 
individual made economic trade-offs in 30 days prior to admission. Educational 
attainm ent was grouped according to number of years of formal education: 0-8 years, 9-13 
years and 14 or more years. Living arrangem ent prior to admission was grouped to form 
four categories: lived alone, lived with family, lived w ith others [not family) and lived in a 
group setting. Prior residential status was coded during assessment into one of twelve 
groups: private home/apartment, rented room, board and care/assisted living/group 
home/mental health residence, facility for those w ith intellectual disability, psychiatric 
hospital or unit, homeless [w ith or w ithout shelter), long-term care facility [nursing home), 
rehabilitation unit/hospital, hospice, acute unit/hospital, correctional facility, and other.
29
Functional Characteristics Functional characteristics include cognitive status and self- 
care skills. Cognitive functioning is determined through an embedded scale -  the Cognitive 
Performance Scale (CPS), v/hich is based on short-term memory/recall abilities, daily- 
decision making skills, expression and self-performance in eating (Morris et al., 1994). 
Scores of cognitive performance are measured on a 7-point scale; from intact (0) and 
borderline intact (1), to mild (2), moderate (3), and moderate-severe impairment (4), to 
severe (5) and very severe impairment (6). Self-care is measured using the Activities of 
Daily Living (ADL) Self-Performance Hierarchy Scale as v/ell as the Instrumental Activities 
of Daily Living (lADL) Summary Index. The Activities of Daily Living measured include: 
personal hygiene (ie. combing hair, brushing teeth, and shaving); v/alking; use of 
v/heelchair; toilet use; and eating habits. The ADL-Hierarchy Scale aims to reflect the 
disablement process by differentiating early loss items (i.e. personal hygiene) from late loss 
items (i.e. eating) (Morris, Fries & Morris, 1999). An algorithm is used to compute a 7- 
point scale that differentially accounts for early loss items, v/hich receive a lesser score, 
than late loss items. The scale computed based on the 4 items ranges from: the ability to 
perform the task independently (0), to supervision (1), to limited assistance (2), to 
extensive assistance 1 (3), to extensive assistance 2 (4) to dependent (5) and total 
dependence (6). The Instrumental Activities of Daily Living (lADL) Summary Index 
includes items on: meal preparation; performing ordinary housev/ork; managing 
medications; transportation (ability to use public transportation, arrange other 
transportation or drives self); financial management; shopping; and use of telephone. 
Scores based on lADL activities are summative and range from 0 to 42, w ith higher scores 
reflecting greater difficulty in performing lADLs.
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Clinical Characteristics Clinical characteristics examined include those related to both 
mental health and physical health. M ental health variables measured include; mental state 
indicators (including depression, positive and negative symptoms]; behaviour disturbance; 
and Global Assessment of Functioning (OAF] scores. The Depression Rating Scale (DRS) is 
a summative scale, based on the presence of 7 items (negative statements, persistent anger, 
expressions of unrealistic fears, repetitive health complaints, repetitive anxious complaints, 
facial expression and crying or tearfulness], and is a clinical indicator of possible 
depression (Burrows, Morris, Simon, Hirdes & Phillips, 2000]. Scores on the DRS range 
from 0 to 14, w ith scores of 3 or more indicating possible depression (Burrows et al.,
2000]. The Positive Symptoms Scale (PSS] is a summative scale that provides information 
on psychosis based on the presence of 4 items (hallucinations, command hallucinations and 
abnormal thought process/form] over the three day period prior to assessment. The 
scores on the PSS range between 0 and 8, w ith higher scores being representative of 
elevated levels of positive symptoms. The Negative Symptom Scale (NSS] is a summative 
scale that similarly provides information on withdrawal based on 4 items (anhedonia, loss 
of interest, lack of motivation, and reduced interaction] over the three days prio r to 
assessment. The scores on the NSS range from 0 to 8, with higher scores representing 
elevated levels of negative symptomatology. Behavioural disturbances are measured based 
on the aggressive behaviour scale (ABS). Scores on the ABS are based on the occurrence of 
4 items: verbal abuse, physical abuse, socially disruptive behaviour and resistance of care. 
The summative scores range from 0-12, where higher scores represent increased 
behaviour disturbance. Scores of 1 to 4 are indicative of mild to moderate aggressive 
behaviour, w ith scores of S or more indicating more severe aggressive behaviour. The
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Global Assessment of Functioning (GAF) score ranges from 0-100, w ith lower scores 
representing decreased social, occupational and psychological functioning (DSM-IV-TR), 
and has been demonstrated to be a good measure of symptoms and social functioning in 
individuals w ith schizophrenia (Startup, Jackson and Bendix, 2002).
Physical health variables examined include: presence of various health conditions 
over the last 3 days (i.e. headache, dizziness or lightheadedness; shortness of breath; chest 
pain; blurred vision; dry mouth; increase or decrease in appetitive; urinary problems; 
nausea; vomiting; constipation; daytime drowsiness/sedation; fatigue/weakness; impaired 
balance; emergent conditions (i.e. fever, itch or rash); and edema); physical activity; vision; 
nutritional problems; extra pyramidal symptoms (i.e increase/decrease in motor activity 
and muscle contractions); sexual dysfunction; skin or food problems; pain; and presence of 
other medical diagnosis. Health conditions are measured on a 3-point scale ranging from 
indicator not exhibited in last 3 days (0) to exhibited on 1-2 of last 3 days (1) to exhibited 
on each of last 3 days (2). To facilitate data analysis, health conditions were collapsed into a 
dichotomous variable and recorded as exhibited in last three days (1 and 2) and not 
exhibited on any of the last 3 days (0). Data on physical activity, or stamina, was measured 
over the 3 days prior to assessment and was scored as: more than 2 hours (0), 1-2 hours 
(1), less than 1 hours (2) and none (3). Vision was scored on a five-point scale from 
adequate (0) to impaired (1), moderately impaired (2), highly impaired (3) and severely 
impaired (4). Vision ratings are conducted w ith the person utilizing normal aides (i.e., 
glasses, hearing aid, or other appliance). Vision was dichotomized to form two categories, 
adequate vision (0) and impaired vision (1-4). The presence of nutritional problems were 
assessed as: weight loss of 5% or more in the last 30 days or 10% or more in the last 180
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days; weight gain of 5% or more in the last 30 days or 10% or more in the last 180 days; 
insufficient fluid, less than 1,000 cc per day; and noticeable decrease in the amount of food 
patient usually eats or fluid usually consumed in the last 3 days and coded as either no (0) 
or yes (1). Extra pyramidal symptoms were measured as either being present in the last 3 
days (1) or not present during the last 3 days (0). Sexual dysfunction was measured as 
either being present (1) or not (0] through the person's report of persistent difficulty in 
sexual functioning in the past 30 days. Whether the person has experienced any skin or 
foot conditions over the past 30 days was recorded as no (0] or yes (1). The embedded 
Pain Scale (PS) utilizes two measures, frequency and intensity of pain over the previous 3 
days, to derive a score ranging from 0-3 (Fries, Simon, Morris, Flodstrom & Bookstein,
2001). Scale scores indicate no pain (0), to less than daily pain (1), to daily pain but not 
severe (2), to severe daily pain (3). Presence of medical conditions currently subject to 
active treatment and monitoring were coded utilizing the ICD-IO-CA standard. Medical 
conditions were combined into groups including: cardiopulmonary, neurological, 
musculoskeletal, gastrointestinal, infections and other conditions (see Appendix A). 
Summing the number of medical diagnoses was also completed to gauge the total number 
of medical conditions an individual had. Categories were formed for the number of medical 
diagnoses as no medical diagnosis, 1-2 medical diagnoses, and greater than 3 medical 
diagnosis.
Social Characteristics Social characteristics examined include: relationship w ith 
immediate family and presence of social supports (family/friends). Whether the person's 
relationship with immediate fam ily  members is disturbed or dysfunctional is scored as no 
belief that relationships are disturbed (0), only patient believes (1), family, friends and
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others believe relationships are dysfunctional (2] or both patient and 
fam ily/friends/others believe that relationships are dysfunctional. Presence of problems 
w ith social relationships is scored as either no problems (0) or problems (1). Whether the 
person has social supports (family/friends) who are w illing to provide assistance w ith a 
number of activities including help w ith child care or dependents, supervision for personal 
safety, crisis support and support w ith ADLs or lADLS is examined. The presence of social 
supports is scored as being not needed (0), regular support (1), occasional support (2), or 
no support (3).
Medication Adherence Medication use and adherence data includes: history of 
adherence to medication; refusal to take prescribed medications; stopping psychotropic 
medication due to side effects; and use of acute control medications. History o f medication 
adherence is measured over the month prior to admission and is scored as always adherent 
(0), adherent 80% of the time or more (1), adherent less than 80% of the time including 
failure to purchase prescribed medications (2), no medications prescribed (3) or unknown 
status (8). Records w ith unknown medication status or where individuals were not taking 
any medication were excluded. Refusal to take some or a ll prescribed medication was 
measured over the previous 3 days and was scored as no, did not refuse to take medication,
(0) or yes, refused to take medications (1). Whether a patient stopped taking psychotropic 
medication due to side effects or intentionally misused medications (prescription or over- 
the-counter) in the previous 3 months was scored as no (0) or yes (1). The use of acute 
control medications to prevent harm to self or others was coded based on the number of 
times it had occurred over the previous 3 days. Therefore, if  psychotropic dugs were used
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as an immediate intervention 3 times, a code of 3 was entered. If medications were utilized 
more than 9 times in an acute manner, a code of 9 was entered.
Service Utilization Mental health service utilization was also assessed as part of the data 
analysis and included; number of recent and lifetime psychiatric admissions; time since last 
discharge; amount of time hospitalized (in a psychiatric unit in the past 2 years); time since 
last contact w ith community mental health agency or professional; and age at first 
hospitalization. Present service utilization w ill also be examined. This includes number of 
days having contact (of at least 15 minutes) over the previous 7 days or since admission 
with: psychiatrist, nurse practitioner or MD (non psychiatrist), social worker, psychologist 
or psychometrist, occupational therapist, recreation therapist, addiction counselor or 
dietician. In addition, the focus of interventions being provided to patients w ill be explored. 
The types of interventions measured include community reintegration, social/family 
functioning, psychological rehabilitation, detoxification, alcohol/drug treatment or 
smoking cessation, vocational counseling, anger management, eating disorder, behavioural 
management, post traumatic stress, pain management and alternative/non-traditional 
therapy.
Quality of Life
A number of select subjective and objective indicators of quality of life are found in 
the RAl-MH and include: self-rated health, quality of social relationships, social contacts 
and participation in meaningful activities. Self-rated health, a subjective indicator of quality 
of life, is assessed by asking the individual if  he/she has poor health. The subsequent 
indicators are considered objective measures of quality of life. Measures of quality o f social
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relationships include: whether the person has a confidant; person is hostile or critical of 
family/friends; person is hostile or critical of other patients/staff; family/friends are 
hostile or critical of the person. The presence o f potential problems with social relationships 
were measured as present (1) or not present (0). Two measures of social contact w ith 
family/friends are measured and include: visit by long standing social relation/fam ily 
member and telephone or e-mail contact w ith long-standing social relation/family 
member. The length of time since a visit or telephone/e-mail is used to score contact w ith 
social relationships. The scores range from occurred w ithin last 3 days (0), to occurred 
w ithin last week (1), to occurred w ithin last month (2), and to last occurred more than a 
month ago. Participation in social activities o f long standing interest was measured and 
scored as above, utilizing length of time since last participation as an indicator of 
participation. A second meaningful activity considered in the RAl-MH is current 
employment status and is scored as employed (0), unemployed but seeking employment
(1), unemployed and not seeking employment (2), other (3), or employment status 
unknown (4).
The Depression Rating Scale (DRS) includes many items (i.e. negative statements, 
persistent anger, expressions of unrealistic fears, repetitive health complaints, and 
repetitive anxious complaints) found in measures of Negative Affect (NA) and thus served 
as a proxy for Negative Affect.
Analysis
All individuals meeting inclusion criteria were profiled using descriptive statistics to 
provide a basic overview and features of the patient population. Characteristics of persons
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with the comorbid conditions were compared to persons with schizophrenia and no 
diabetes using chi-square analysis and unpaired t-tests. Tests of normality were performed 
to determine whether ordinal and continuous data was normally distributed based on the 
Kolmogrov-Smirnov and Cramer-von Mises tests for normality. Data that was determined 
to be non-normal was analyzed using the Wilcoxon-Mann-Whitney test to compare groups.
Bivariate regression analyses were performed to examine the impact of diabetes on 
select measures of quality of life. Select variables that have been previously associated 
w ith a diagnosis of diabetes and those that were significant (p<0.05) were then entered 
into a multivariate logistic model that evaluated the impact of diabetes after controlling for 
potential confounders. Variables entered into the model included: age, gender, depression, 
positive symptoms, negative symptoms, marital status, number of health problems, 
physical activity and pain.
All tests were performed using a 2-sided a  level of 0.05. This level of significance 
was used to ensure that the results were powerful given the large number of comparisons 
made while not excluding potentially significant results, which may occur w ith a lower a  
level. All data analysis was generated using SAS software. Version 9.1.3 Service Pack 2 of 
the SAS System for Windows. Only significant results (p<0.05) w ill be reported in the text.
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Chapter 3: RESULTS
The entire data set consisted of 39,233 observations, of which 13,088 individuals 
(33.35%) had a diagnosis of schizophrenia or other psychotic disorder and 1863 
individuals (4.75%) had a diagnosis of diabetes. Of persons with a diagnosis of 
schizophrenia, 630 individuals (4.81%) had a comorbid diagnosis of diabetes. Only 
records w ith a diagnosis of schizophrenia were retained for data analysis. Overall, 
individuals w ith schizophrenia consisted largely persons who were male (58.5%), single 
(83.1%), w ith a mean age of 42.1 years (± 15.3 years) and 9 to 13 years of education 
(56.1%).
Comparison of Personal Characteristics
As summarized in table 3.1, individuals w ith the comorbid conditions, as compared 
to individuals w ith no diabetes, were more often female {y} [1] = 18.9; p<0.0001), over 35 
years of age (x^ [2] = 278.0; p<0.0001), have a BMI greater than 25 (x^ [2] = 191.8; 
p<0.0001), be married/have a partner (x^ [1] = 9.9; p<0.01), unemployed (x^ [1] = 31.8; 
p<0.0001), have fewer years of formal education (x^ [2] = 39.3; p<0.0001), live in a group 
setting, but less likely to live with others (not family) (x^ [3] = 73.5; p<0.0001), and have 
resided in long-term care, acute unit/hospital, or board and care/assisted living/group 
home/mental health residence prior to admission (x^ [11] = 101.8; p<0.0001).
Table 3.1 Comparison o f Personal Characteristics between Individuals With and W ithout 
Diabetes, Percent Within Group (NJ
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Gender 18.88 [1] <0.0001
Male 50.16 316) 58.90 (7338)
Female 49.84 314) 41.10 (5120)
BMI 191.83 [3] <0.0001
<20 4.92 31) 10.64 (1326)
20-24 15.40 97) 34.89 (4346)
25-29 33.33 210) 29.28 (3648)
>30 46.35 292) 25.29 (3138)
Marital status 9.88 [1] 0.0017
M arried / partner/significant other 21.43 135) 16.62 (2071)
Single/widowed/separated/divorced 78.57 495) 83.38 (10387)
Employment status 31.80 [1] <0.0001
Employed 5.63 26) 15.14 (1501)
Unemployed 94.37 436) 84.86 (8416)
Economic trade-offs 3.06(1] ns
No trade off in last 30 days 95.40 601) 93.67 (11669)
Trade off in last 30 days 4.60 29) 6.33 (789)
Education, years 39.30 [2] <0.0001
0-8 21.75 117) 12.75 (1365)
9-13 54.28 292) 56.72 (6074)
>14 23.98 129) 30.53 (3269)
Living arrangements 73.53 [3] <0.0001
Lived alone 35.24 222) 34.49 (4297)
Lived with family 20.32 128) 17.47 (2176)
Lived with others (not family) 16.35 103) 29.99 (3736)
Lived in group setting 28.10 177) 18.05 (2249)
(table continues)
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Characteristic Diabetes fN=630] No Diabetes [N=12,4581 x'[dn P-value
Prior Residential Status 101.75[11] <0.0001
Private home/apartment 59.52 (375) 68.78 (8569)
Rented room 3.02 (19) 4.82 (600)
Board and care/assisted living/group 
home/mental health residence 13.65 (86) 8.69 (1082)
Facility for intellectual disability 0.48 (3) 0.26 (32)
Psychiatric hospital of unit 4.29 (27) 3.13 (390)
Homeless (with or without shelter) 3.49 (22) 4.93 (614)
Long-term care facility 4.92 (31) 1.37 (171)
Rehabilitation unit/hospital 0.00 CO) 0.08 (10)
Hospice 0.00 CO) 0.10 (12)
Acute unit/hospital 7.62 C48) 4.17 (519)
Correctional facility 1.27 C8) 1.73 (216)
Other 1.75 C ll) 1.95 (243)
Note: The employment status variable excludes records that identified as 'other' or ‘unknown’ employment 
status [diabetes = 168 (26.7%), no diabetes = 2,541 (20.4% )).
Comparison of Functional Characteristics
The Kolmogorov-Smirnov (KS) and Cramer-von Mises (CS) tests for normality (table 
3.2) indicate that the Cognitive Performance Scale (CPS), the Activities of Daily Living 
(ADL) Hierarchy and Instrumental Activities of Daily Living (lADL) Summary Index are not 
normally distributed and thus the Wilcoxon-Mann-Whitney sign rank test was used to 
analyze these variables. The Wilcoxon-Mann-Whitney test (table 3.3) indicates that scores 
differ significantly between individuals with diabetes and without diabetes on the CPS [W  = 
4.75, p<0.0001), ADL [_W= 4.95, p<0.0001) and the lADL ( W =  7.92, p<0.0001). Individuals 
w ith the comorbid conditions had higher scores on the CPS, ADL and lADL scales when 
compared to individuals with no diabetes.
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Table 3.2 Test fo r  Normality, Functional Characteristics
Kolmogorov-Smirnov Cramer-von Mises
Characteristic Test Statistic P-value Test Statistic P-value
Cognitive Performance Scale 0.274 <0.0100 213.31 <0.0050
Activities of Daily Living 0.455 <0.0100 597.88 <0.0050
Instrumental Activities of Daily Living 0.227 <0.0100 194.48 <0.0050
Table 3.3 Wilcoxon-Mann-Whitney Sign Rank Test Examining Between Group (Diabetes, No 
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Instrumental Activities of Daily Living 
Mean (SD) 8.05 (8.73) 5.79 (7.83)
7.92 <0.0001
Comparison of Clinical Characteristics
M ental Health Tests for normality indicate that measures of mental health, including
the Depression Rating Scale (DRS), Positive Symptom Scale (PSS), Negative Symptom Scale 
(NSS), Aggressive Behaviour Scale (ABS), and the Global Assessment of Functioning (GAF) 
are not normally distributed (table 3.4). The Wilcoxon-Mann-Whitney test was therefore 
utilized and the results are presented in table 3.5, which indicates that scores on the 
Positive Symptom Scale (PSS) differ between individuals with and w ithout diabetes (W = - 
2.23, p<0.05) and that individuals with diabetes experience lower levels of psychosis.
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Table 3.4 Test fo r  Normality, Mental Health Characteristics
Characteristic
Kolmogorov-Smirnov Cramer-von Mises
Test Statistic P-value Test Statistic P-value
Depression Rating Scale 0.176 <0.0100 65.3 <0.0050
Positive Symptom Scale 0.114 <0.0100 34.79 <0.0050
Negative Symptom Scale 0.222 <0.0100 120.9 <0.0050
Aggressive Behaviour Scale 0.323 <0.0100 273.63 <0.0050
Global Assessment of Functioning (GAF] 0.0937 <0.0100 15.14 <0.0050
Table 3.5 Wilcoxon-Mann-Whitney Sign Rank Test Examining Between Group [Diabetes, No 












































Global Assessment of Functioning (GAF) 
Mean (SD) 36.68 (14.91) 37.04 (15.85)
-0.37 ns
Physical Health Table 3.6 provides statistics related to health conditions and indicates 
that individuals with diabetes are more likely to experience shortness of breath (x^ [1] = 
26.65; p<0.0001), chest pain/pressure [1] = 4.32; p<0.05), blurred vision [1] = 4.61; 
p<0.05), difficulty urinating/frequent urination (x^ [1] = 10.74; p<0.01), impaired 
balance/ataxia (x^ [1] = 4.74; p<0.05) and edema (x^ [1] = 13.34; p<0.01).
42
Table 3.6 Health Conditions Experienced by Individuals With and W ithout Diabetes in the 
Three Days Prior to Assessment, Percent Within Group (N )
Health Condition Diabetes fN=630) No Diabetes (N=12,458) X' [df] P-value
Headache 0.091 [1] ns
Not exhibited in last 3 days 90.16 (568) 90.52 (11277)
Exhibited in last 3 days 9.84 (62) 9.48 (1181)
Dizziness/vertigo or lightheadedness 2.98 [1] ns
Not exhibited in last 3 days 91.59 (577) 93.35 (11630)
Exhibited in last 3 days 8.41 (53) 6.65 (828)
Shortness of breath 26.65 [1] <0.0001
Not exhibited in last 3 days 92.70 (584) 96.61 (12036)
Exhibited in last 3 days 7.30 (46) 3.39 (422)
Chest pain/pressure 4.32 [1] 0.0377
Not exhibited in last 3 days 96.98 (611) 98.15 (12227)
Exhibited in last 3 days 3.02 (19) 1.85 (231)
Blurred Vision 4.61 [1] 0.0318
Not exhibited in last 3 days 95.71 (603) 97.18 (12107)
Exhibited in last 3 days 4.29 (27) 2.82 (351)
Dry mouth 0.36 [1] ns
Not exhibited in last 3 days 90.48 (570) 89.79 (11179)
Exhibited in last 3 days 9.52 (60) 10.21 (1279)
Increase/decrease in normal appetite 2.47 [1] ns
Not exhibited in last 3 days 88.73 (559) 86.55 (10782)
Exhibited in last 3 days 11.27 (71) 13.45 (1676)
Difficulty urinating/frequent urination 10.74 [1] 0.001
Not exhibited in last 3 days 95.40 (601) 97.52 (12149)
Exhibited in last 3 days 4.60 (29) 2.48 (309)
Nausea 0.076 [1] ns
Not exhibited in last 3 days 96.51 (608) 96.71 (12048)
Exhibited in last 3 days 3.49 (22) 3.29 (410)
Vomiting 0.24 [1] ns
Not exhibited in last 3 days 97.94 (617) 98.20 (12234)
Exhibited in last 3 days 2.06 (13) 1.80 (224)
Constipation 3.80 [1] ns
Not exhibited in last 3 days 93.17 (587) 94.93 (11827)
Exhibited in last 3 days 6.83 (43) 5.07 (631)
Diarrhea 2.75 [1] ns
Not exhibited in last 3 days 96.98 (611) 97.95 (12203)
Exhibited in last 3 days 3.02 (19) 2.05 (255)
Daytime drowsiness/sedation 1.97 [1] ns
Not exhibited in last 3 days 84.44 (532) 82.26 (10248)
Exhibited in last 3 days 15.56 (98) 17.74 (2210)
(tab le  continues)
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Characteristic Diabetes [N=630] No Diabetes (N=12,4583 [df] P-value
Fatigue/weakness 2.58 [1] ns
Not exhibited in last 3 days 82.22 (5183 84.6 (105393
Exhibited in last 3 days 17.78 (1123 15.4 (19193
Impaired balance/ataxia 4.74 [1] 0.0294
Not exhibited in last 3 days 92.22 (5813 94.30 (117483
Exhibited in last 3 days 7.78 (493 5.70 (7103
Emergent conditions 0.43 [1] ns
Not exhibited in last 3 days 97.30 (6133 97.70 (121723
Exhibited in last 3 days 2.70 (173 2.30 (2863
Edema 13.34 [1] 0.0003
Not exhibited in last 3 days 96.03 (6053 98.11 (122233
Exhibited in last 3 days 3.97 (253 1.89 (2353
Information on physical activity, vision, nutritional problems, extra pyramidal 
signs/symptoms, sexual functioning, skin or foot problems and pain are presented in table 
3.7 and provide comparisons between individuals w ith diabetes and those w ithout 
diabetes. Individuals w ith diabetes were more likely to engage in fewer than 2 hours of 
physical activity in the previous 3 days (x^ [3] = 25.38; p<0.0001], have impaired vision (x^ 
[1] = 32.31; p<0.0001], experience skin or foot problems (x^ [1] = 18.68; p<0.0001], and 
experience higher rates of pain ([3] = 16.06; p<0.01]. Individuals w ith diabetes were also 
more likely to demonstrate decreased motor activity in the form of slow, shuffling gait (x^ 
[1] = 12.37; p<0.0001).
Table 3.7 Analysis o f Clinical Characteristics Related to Physical Health Comparing 
Individuals With and W ithout Diabetes, Percent Within Group (N ]
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Characteristic Diabetes rN=630] No Diabetes fN=12,4581 fdfj_____ P-value
Physical activity 
More than 2 hours 
1-2 hours 



















Vision 32.31 [1] <0.0001
Adequate 88.41 (557) 94.03 (11714)
Impaired 11.59 (73) 5.97 (744)
Nutritional Problems
Weight Loss 0.29 [1] ns
No 4.32 (564) 88.83 (11067)
Yes 10.48 (66) 11.17 (1391)
Weight Gain 0.74 [1] ns
No 4.61 (603) 96.37 (12006)
Yes 4.29 (27) 3.63 (452)
Insufficient Fluids 1.30 [1] ns
No 96.83 (610) 95.91 (11948)
Yes 3.17 (20) 4.09 (510)
Decrease in Food 3.48 [1] ns
No 94.60 (596) 92.62 (11539)
Yes 5.40 (34) 7.38 (919)
Extra pyramidal symptoms
Akathasia 0.078 [1] ns
No 95.08 (588) 95.32 (11875)
Yes 4.92 (31) 4.68 (583)
Dyskinesia 3.58 [1] ns
No 96.83 (610) 97.94 (12201)
Yes 3.17 (20) 2.06 (257)
Tremor 3.29 [1] ns
No 94.29 (594) 95.79 (11933)
Yes 5.71 (36) 4.21 (525)
Rigidity 0.0005 [1] ns
No 98.25 (619) 98.24 (12239)
Yes 1.75 (11) 1.76 (219)
Slow Shuffling Gait 12.37 [1] 0.0004
No 93.65 (590) 96.38 (12007)
Yes 6.35 (40) 3.62 (451)
Bradykinesia 0.52 [1] ns
No 96.83 (610) 97.30 (12122)
Yes 3.17 (20) 2.70 (336)
Dystonia 0.16 [1] ns
No 99.05 (624) 98.88 (12318)
Yes 0.95 (6) .......... .. 1.12 (140)
(tab le  continues)
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Characteristic Diabetes (N=630) No Diabetes (N=12,458) X' Idfl P-value
Sexual Functioning (last 30 days) 0.86 [1] ns
No dysfunction 96.35 (607) 97.00 (12084)
Dysfunction 3.65 (23) 3.00 (374)
Skin or Foot Problems 18.68 [1] <0.0001
No 86.67 (546) 91.62 (11414)
Yes 13.33 (84) 8.38 (1044)
Pain Scale (PS) 16.06 [3] 0.0011
No pain 80.48 (507) 85.12 (10604)
Less than daily pain 8.89 (56) 8.07 (1005)
Daily pain, not severe 9.37 (59) 5.68 (707)
Severe daily pain 1.27 (8) 1.14 (142)
Table 3.8 provides information on categories of medical conditions [see Appendix 
A). In comparison to individuals w ithout diabetes, individuals with diabetes more often 
had a cardiopulmonary condition [%̂  [1] = 414.02; p<0.0001), neurological condition (x^ 
[1] = 14.71; p<G.Gl), musculoskeletal condition [x^ [1] = 36.71; p<O.OGGl), gastrointestinal 
condition [x^ [1] = 12.49; p<G.Gl), or other condition [x^ [1] = 194.48; p<G.GGGl). 
Individuals w ith the comorbid conditions were also more likely to have a multitude of 
medical diagnoses than were individuals w ith schizophrenia only [x^ [2] = 332.76; 
p<G.OGGl).
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Table 3.8 Medical Diagnoses in Individuals With and W ithout Diabetes, Percent Within Group 
(N )
Medical Diagnosis Diabetes fN=630) No Diabetes (N=12,458) X2 Idfl P-value
Cardiopulmonary 24.41 (179] 6.60 (822) 414.02 [1] <0.0001
Neurological 4.44 (28] 2.13 (265) 14.71 [1] 0.0001
Musculoskeletal 5.40 (34] 1.89 (235) 36.71 [1] <0.0001
Gastrointestinal 4.13 (26] 2.04 (254) 12.49 [1] 0.0004
Infection 0.95 (6) 1.58 (197) 1.55 [1] 0.213
Other 23.97 (151] 7.92 (987) 194.48 [1] <0.0001
Total number of
medical diagnoses 332.76 [2] <0.0001
0 53.97 (340] 82.62 (10293)
1-2 42.70 (269] 16.60 (2068)
>3 3.33 (21) 0.78 (97) ....
Comparison of Social Characteristics/Involvement
Table 3.9 provides information pertaining to social characteristics and involvement 
comparing individuals w ith diabetes to individuals w ithout diabetes. With respect to social 
relationships, individuals w ith the comorbid conditions were more likely to report having a 
confidant [1] = 4.85; p<0.05). Friends/family of individuals w ith the comorbid 
conditions were less likely to report feeling overwhelmed by the patient's illness [1] = 
7.94; p<0.01). In regards to the availability of social supports, individuals w ith diabetes are 
more likely to need supervision for personal safety, while having support occasionally 
[1] = 12.34; p<0.01), and need support w ith ADLs or lADLs, while having support 
occasionally [1] = 35.59; p<0.0001).
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Table 3.9 Social Characteristics and Involvement o f Individuals With and W ithout Diabetes, 
Percent Within Group (N )
Characteristic Diabetes (N=630) No Diabetes (N=12,458) X' (df| P-value
Family Roles 7.73 [3] ns
Belief not present 69.34 (440) 65.41 (8149)
Only Patient Believes 10.63 (67) 12.2 (1520)
Family/friends/others believe 8.73 (55) 8.32 (1037)
Both patient and others believe 10.79 (68) 14.06 (1752)
Social Relationships
Patient reports having no confidant 4.85 [1] 0.0280
No 84.44 (532) 80.92 (10081)
Yes 15.56 (98) 19.08 (2377)
Family/friends overwhelmed by patients illness 7.94 [1] 0.0048
No 65.4 (412) 59.76 (7445)
Yes 34.6 (218) 40.24 (5013)
Patient is hostile/critical towards family/friends 1.31 [1] ns
No 84.13 (530) 82.35 (10259)
Yes 15.87 (100) 17.65 (2199)
Patient is hostile/critical towards other patients/staff 0.67 [1] ns
No 88.57 (558) 89.6 (11162)
Yes 11.43 (72) 10.4 (1296)
Family/friends are hostile toward/critical of patient 0.050 [1] ns
No 96.03 (605) 95.85 (11941)
Yes 3.97 (25) 4.15 (517)
Staff reports frustration in dealing with patient 0.898 [1] ns
No 90.95 (573) 92.01 (11462)
Yes 9.05 (57) 7.99 (996)
Family/friends require unusual amount of facility/staff time 0.0022 [1] ns
No 96.67 (609) 96.7 (12047)
Yes 3.33 (21) 3.3 (411)
(table continues)
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Characteristic Diabetes (N=630) No Diabetes (N=12,458) X^df] P-value
Available Social Supports
Help with child care, other dependents 5.59 [1] ns
Not needed 91.27 (575) 89.96 (11207)
Occasional 3.02 (19) 4.83 (602)
Regular 1.27 (8) 1.55 (193)
No 4.44 (28) 3.66 (456)
Supervision for personal safety 12.34(1] 0.0063
Not needed 33.97 (214) 39.57 (4930)
Occasional 29.52 (186) 25.18 (3137)
Regular 22.86 (144) 23.91 (2979)
No 13.65 (86) 11.33 (1412)
Crisis support 5.83 [1] ns
Not needed 25.08 (158) 24.71 (3078)
Occasional 25.56 (161) 27.24 (3394)
Regular 34.6 (218) 36.33 (4526)
No 14.76 (93) 11.72 (1460)
Support with ADLs or lADLs 35.59 [1] <0.0001
Not needed 46.51 (293) 57.99 (7225)
Occasional 22.22 (140) 15.61 (1945)
Regular 18.1 (114) 15.39 (1917)
No 13.17 (83) 11 (1371)
Comparison of Medication Adherence
Table 3.10 provides information on medication adherence. Individuals w ith 
diabetes, compared to individuals w ith no diabetes, were less likely to have had 
psychotropic drugs used as an acute intervention over the 3 days prior to assessment (x^ 
[3] =8.85;p<0.05).
Table 3.10 History o f Medication Use and Adherence Comparing Individuals With and 
W ithout Diabetes, Percent Within Group (N )
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Characteristic Diabetes fN=630') No Diabetes (N=12,458] X' (dfl P-value
History of medication adherence 1.28 [2] ns
Always adherent 29.18 (164] 31.17 (3108]
Adherent 80%  of time or more 26.16 (147] 24.50 (2443]
Adherent less than 80%  of time 44.66 (251] 44.33 (4420]
Medication refusal, last 3 days 0.023 [1] ns
No, did not refuse medications 77.62 (489] 77.88 (9702]
Yes, refused medications 22.38 (141] 22.12 (2756]
Stopped taking psychotropics due to side 
effects, last 3 months 0.054 [1] ns
No 82.70 (521] 83.06 (10347]
Yes 17.30 (1091 16.94 (21111
Misused medication, last 3 months 2.15 [1] ns
No, did not misuse medications 93.02 (586] 91.34 (11379]
Yes, misused medications 6.98 (44] 8.66 (1079]
Psychotropic medication used for acute 
control, last 3 days 8.85 [3] 0.031
0 81.90 (516] 76.80 (9568)
1-5 15.71 (99] 20.03 (2495]
6-8 1.43 (9] 1.92 (239]
> 9 0.95 (6) 1.25 (1561
Comparison of Service Utilization History
Data regarding past and present service utilization is presented in table 3.11. 
Persons w ith diabetes, in contrast to individuals w ithout diabetes, were more likely to have 
experienced more than 6 lifetime psychiatric admissions [3] = 82.84; p<0.0001), had 
longer periods of time [x^ [4] = 33.33; p<0.0001), and had been admitted for longer periods 
of time [greater than 31 days) in the previous 2 years [x^ [3] =8.47; p<0.05). They were 
also more likely to have had contact w ith community mental health in the 30 days prio r to 
admission [x^ [1] = 26.34; p<0.0001) and were more likely to be over the age of 25 at the 
time of their first overnight hospitalization in a psychiatric unit/hospital [x^ [2] = 73.74;
p<0.0001).
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Table 3.11 Comparison o f Past and Present Service Utilization History between Individuals 
With and W ithout Diabetes, Percent Within Group (N j
Characteristic Diabetes fN =630] No Diabetes (N=12,458] fdf|_____ P-value
Number of recent psychiatric admissions, last 2 years 1.20 [2] ns
0 44.44 (28] 45.51 (5670]
1-2 38.25 (241] 36.18 (4507]
>3 17.30 (109] 18.32 (2281]
Number of psychiatric admissions, lifetime 82.84 [3] <0.0001
0 14.13 (89] 23.29 (2914]
1-3 30.00 (189] 33.75 (4204]
4-5 14.92 (94] 17.48 (2178]
>6 40.95 (258] 25.38 (3162]
Time since last mental health admission 33.33 [4] <0.0001
> 1 year 48.57 (306] 40.68 (5068]
31 days -1  year 29.21 (184] 26.91 (3352]
< 30 days (from other facility] 4.76 (30] 5.47 (681]
< 3 0  days (from same facility] 3.33 (21] 3.56 (443]
Not applicable 14.13 (89] 23.39 (2914]
Amount of time in psychiatric unit/hospital, last 2 years 8.47 [3] 0.0373
No admission in last 2 years 44.44 (280] 43.32 (5670]
< 3 0  days 23.81 (150] 26.25 (3435]
31 days -1  year 26.67 (168] 21.36 (2796]
> 1 year 5.08 (32] 4.26 (557]
Time sine last contact with community mental health, last year 26.34 [2] <0.0001
No contact in last year 30.95 (195] 41.11 (5121]
31 days or more 21.75 (137] 19.62 (2444]
30 days or less 47.3 (298] 39.28 (4893]
Age at first overnight hospitalization in psychiatric unit/hospital 73.74 [2] <0.0001
0-24 33.81 (213] 47.53 (5921]
25-64 58.73 (370] 49.56 (6174]
65+ 7.46 (47] 2.91 (363]
Table 3.12 provides information on the focus of intervention over the 7 days prio r to 
assessment or since admission. Individuals w ith diabetes were less likely to have received 
interventions that focused on detoxification [x^ [1] = 7.39; p<0.01) and behavioural 
management [x^ [1] = 5.06; p<0.05), but were more likely to have received pain 
management [x^ [1] = 4.78; p<0.05) than individuals without diabetes.
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Table 3.12 Comparison o f M ajor Focus o f Interventions, in Seven Days Prior to Assessment or 
Since Admission i f  Less Than Seven Days, between Individuals With and W ithout Diabetes, 
Percent Within Group (N )
Characteristic Diabetes fN=6301 No Diabetes fN=12,458) XMdf] P-value
Community reintegration 0.101 [1] ns
Not received 53.81 339) 54.45 6784)
Received 46.19 291) 45.55 5674)
Social/family functioning 0.878 [1] ns
Not received 64.29 405) 62.43 7778)
Received 35.71 225) 37.57 4680)
Psychological rehabilitation 0.779 [1] ns
Not received 57.94 365) 59.70 7438)
Received 42.06 265) 40.30 5020)
Detoxification
Not received 97.78 616) 95.50 11898) 7.39 [1] 0.0066
Received 2.22 14) 4.50 560)
Alcohol/smoking/drug treatment
Not received 92.22 581) 89.82 11190) 3.82 [1] ns
Received 7.78 49) 10.18 1268)
Vocational counseling 0.359 [1] ns
Not received 97.30 613) 96.88 12069)
Received 2.70 17) 3.12 389)
Anger management
Not received 91.27 575) 89.80 11187) 1.43 [1] ns
Received 8.73 55) 10.20 1271)
Eating disorder 0.549 [1] ns
Not received 98.73 622) 98.35 12252)
Received 1.27 8) 1.65 206)
Behavioural management 5.06 [1 0.0245
Not received 81.75 515) 77.95 9711)
Received 18.25 115) 22.05 2747)
Post-traumatic stress 0.163 [1] ns
Not received 98.41 620) 98.19 12233)
Received 1.59 10) 1.81 225)
Pain management 4.78 [1] 0.0288
Not received 91.90 579) 94.04 11715)
Received 8.10 51) 5.96 743)
Alternative/non-traditional
therapy 1.64 [1] ns
Not received 97.30 613) 98.03 12213)
Received 2.70 17) 1.97 245)
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Results of information collected on contact w ith formal care are presented in table 
3.13. Individuals w ith the comorbid conditions, compared to individuals w ith 
schizophrenia only, were more likely to have had contact w ith a nurse practitioner or MD 
(non-psychiatrist) (%̂  [2] = 32.77; p<0.0001), occupational therapist (x^ [2] = 7.75; p<0.05), 
recreational therapist (x^ [2] = 7.17; p<0.05) and dietician (x^ [2] = 55.06; p<0.0001).
Table 3.13 Comparison o f Number o f Days o f Forma! Care, in Seven Days Prior to Assessment 
or Since Admission, between Individuals With and W ithout Diabetes, Percent Within Group 
(N )
Characteristic Diabetes fN=630) No Diabetes (N=12,458) X 'm P-value
Psychiatrist 2.16 [2] ns
0 5.87 (37) 5.25 (654)
1-4 79.05 (498) 81.39 (10139)
5-7 15.08 (95) 13.36 (1665)
Nurse Practitioner of MD 32.77 [2] <0.0001
0 41.11 (259) 52.66 (6560)
1-4 55.56 (350) 44.17 (5503)
5-7 3.33 (21) 3.17 (395)
Social Worker 0.993 [2] ns
0 48.41 (305) 50.19 (6253)
1-4 47.30 (298) 46.03 (5734)
5-7 4.29 (27) 3.78 (471)
Psychologist or Psychometrist 0.0331 [2] ns
0 93.97 (592) 93.93 (11702)
1-4 5.56 (35) 5.54 (690)
5-7 0.48 (2) 0.53 (66)
Occupational Therapist 7.75 [2] 0.021
0 80.00 (504) 82.81 (10316)
1-4 18.10 (114) 16.27 (2027)
5-7 1.90 (12) 0.92 (115)
Recreation Therapist 7.17 [2] 0.028
0 70.79 (446) 75.36 (9388)
1-4 25.71 (162) 22.07 (2749)
5-7 3.49 (22) 2.58 (321)
Addiction Counselor 0.041 [2] ns
0 98.25 (619) 98.15 (12227)
1-4 1.59 (10) 1.69 (211)
5-7 0.16 (1) 0.16 (20)
Dietician 55.06 [2] <0.0001
0 88.57 (558) 95.12 (11850)
1-4 10.79 (68) 4.74 (590)
5-7 0.63 .(i) 0.14 (18)
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Quality of Life
Bivariate logistic regression was performed to assess the impact of diabetes on 
select quality of life indicators [table 3.14). On its own, diabetes was significantly related 
to: poor self-rated health [OR = 1.97, p <0.0001), having a confidant [OR: 0.78, p < 0.05), no 
visit from long standing social relation/family member in 30 days prior to assessment [OR: 
1.34, p <0.01) and unemployment [OR: 2.99, p<0.0001).
Table 3.14 Bivariate Logistic Regression o f Quality o f Life Indicators with Diabetes as 
Independent Predictor
Quality of life indicator P(SE) Adjusted OR (95% Cl) P-value
Poor self-rated health 0.68 (0.099) 1.97 (1.63-2.40) <0.0001
Patient reports having no confidant -0.26 (0.11) 0.78 (0.63-0.97) 0.028
Patient is hostile towards family/friends -0.13(0.11) 0.88 (0.71-1.1) ns
Patient is hostile towards other patients/staff 0.11(0.13) 1.11 (0.86-1.43) ns
Family/friends are hostile toward patient -0.046 (0.21) 0.96 (0.63-1.44) ns
No visit from social relation/family [last 30 days)
No telephone or e-mail from social relation/family [last 30
0.30 (0.097) 1.34 (1.11-1.62) 0.0023
days) 0.096 (0.11) 1.10 (0.89-1.36) ns
Employment status (unemployed) 1.09 (0.20) 2.99 (2.00-4.46) <0.0001
Depressive symptoms (Negative Affect) -0.097 (0.083) 0.91 (0.77-1.07) ns
Multivariate logistic regression was then performed for each of those four quality of 
life indicators while including possible confounding variables [i.e. age, gender, depression, 
positive symptoms [PSS), negative symptoms [NSS), marital status, number of physical 
health problems, amount of physical activity and pain). The results appear in tables 3.15 
through 3.18.
Diabetes remained significantly related to poor self-rated health [OR: 1.61, p 
<0.001) when controlling for possible confounders [table 3.15). Covariates of poor self- 
rated health, along with diabetes, included: advanced age category [OR: 1.47, p <0.0001),
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depression [OR: 1.63, p<0.0001), negative symptomatology [OR: 1.15, p <0.05], greater 
number of physical health problems [OR: 1.27, p<0.0001), lower amounts of physical 
activity [OR: 1.15, p<0.0001) and higher scores on the pain scale [OR: 1.94, p<0.0001].
Table 3.15 M ultivariate Logistic Regression Examining Independent Contribution o f Diabetes 
on Self-Rated Health, Controlling fo r  Possible Confounders
Predictors 3 (SE) Wald's P-value Odds Ratio
Diabetes (0=no diabetes, l=diabetes) 0.48 (0.11) 18.95 <0.0001 1.61
Age 0.38 (0.045) 72.59 <0.0001 1.47
Gender (0=female, l=m ale) 0.011 (0.058) 0.03 ns 1.01
Depression (0-2, >3) 0.49 (0.060) 65.89 <0.0001 1.63
Positive Symptoms (0-5, >6) -0.060 (0.059) 1.04 ns 0.94
Negative Symptoms (0-5, >6) 0.14 (0.060) 5.03 0.0248 1.15
Marital Status (0=single, l=partner) 0.082 (0.073) 1.27 ns 1.09
Number of Health Problems 0.24 (0.014) 298.38 <0.0001 1.27
Physical Activity 0.14 (0.025) 30.99 <0.0001 1.15
Pain 0.66 (0.036) 346.05 <0.0001 1.94
Individuals with diabetes were significantly more likely to report having a confidant 
[OR: 1.27, p<0.05) than were individuals w ithout diabetes [table 3.16). A number of other 
factors were also associated w ith individuals reporting having no confidant, including: 
depression [OR: 1.30, p<0.0001), positive symptomatology [OR: 1.16, p<0.01), negative 
symptomatology [OR: 1.34, p<0.0001), being married/partnered [OR: 1.53, p<0.0001), 
greater number of health problems [OR: 1.05, p<0.0001) and higher scores on the pain 
scale [OR: 1.09, p<0.05).
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Table 3.16 M ultivariate Logistic Regression Examining Independent Contribution o f Diabetes 
on Patients Report o f Having a Confidant, Controlling fo r  Possible Confounders
Predictors 3(SE) Wald's P-value Odds Ratio
Diabetes (0=no diabetes, l=diabetes) -0.24(0.11) 4.34 0.0371 0.79
Age 0.014 (0.037) 0.15 ns 1.01
Gender (0=female, l=maie) 0.067 (0.048) 1.96 ns 1.07
Depression (0-2, >3) 0.27 (0.049) 29.89 <0.0001 1.30
Positive Symptoms (0-5, >6) 0.15 (0.047) 10.11 0.0015 1.16
Negative Symptoms (0-5, >6) 0.29 (0.049) 35.88 <0.0001 1.34
Marital Status (0=single, l=partner) 0.43 (0.067) 39.97 <0.0001 1.53
Number of Health Problems 0.052 (0.013) 15.34 <0.0001 1.05
Physical Activity -0.012 (0.013) 0.30 ns 0.99
Pain 0.088 (0.034) 5.69 0.0171 1.09
When controlling for possible confounders the association between diabetes and 
visit from a long-standing social relation/fam ily member, the independent association 
between and having no visit in the 30 days prior to assessment was lost [table 3.17).
Table 3.17 M ultivariate Logistic Regression Examining Independent Contribution o f Diabetes 
on Social Relationship as Measured by Visit from  Long-standing Social Relation/Fam ily  
Member (No Visit in Past 30 Days), Controlling fo r  Possible Confounders
Predictors 3 (SE) Wald's yz P-value Odds Ratio
Diabetes (0=no diabetes, l=diabetes) 0.13 (0.10) 1.77 ns 1.14
Age 0.46 (0.037) 154.64 <0.0001 1.59
Gender (0=female, l=m ale) 0.36 (0.050) 53.16 <0.0001 1.44
Depression (0-2, >3) -0.22 (0.050) 20.12 <0.0001 0.80
Positive Symptoms (0-5, >6) 0.042 (0.049) 0.74 ns 1.04
Negative Symptoms (0-5, >6) 0.022 (0.052) 0.18 ns 1.02
Marital Status (0=single, l=partner) 0.89 (0.076) 134.93 <0.0001 2.43
Number of Health Problems -0.029 (0.015) 3.40 ns 0.97
Physical Activity 0.18(0.021) 73.23 <0.0001 1.19
Pain 0.068 (0.039) 3.08 ns 1.07
Diabetes retained a significant association w ith unemployment [table 3.18) 
[0R;2.64, p<0.0001) when controlling for possible confounders. Age [OR: 1.52, p<0.0001), 
gender [being male) [OR: 0.85, p<0.01), depression [OR:0.87, p<0.05), marital status [OR:
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3.21, p<0.0001], number of health problems [OR: 0.96, p<0.05] and physical activity [OR: 
1.12, p<0.0001] were also significantly associated with unemployment.
Tables 3.18 M ultivariate Logistic Regression Examining Independent Contribution o f  
Diabetes on Unemployment, Controlling fo r  Possible Confounders
Predictors 3fSEl Wald’s P-value Odds Ratio
Diabetes (0=no diabetes, l=diabetes) 0.97 (0.21) 21.99 <0.0001 2.64
Age 0.42 (0.051) 68.43 <0.0001 1.52
Gender (0=femaie, l=m aie) -0.16 (0.062) 6.66 0.0098 0.85
Depression (0-2, >3) -0.14(0.061) 5.31 0.0211 0.87
Positive Symptoms (0-5, >6] 0.026 (0.061) 0.18 ns 1.03
Negative Symptoms (0-5, >6) 0.082 (0.065) 1.61 ns 1.09
Marital Status (0=single, 1=partner] 1.17 (0.068) 290.18 <0.0001 3.21
Number of Health Problems -0.037 (0.018) 4.41 0.0358 0.96
Physical Activity 0.11 (0.027) 17.24 <0.0001 1.12
Pain 0.096 (0.054) 3.20 ns 1.1
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Chapter 4: DISCUSSION
The purpose of this study was to determine whether individuals w ith schizophrenia 
and comorbid diabetes differ in terms of personal factors, functional and clinical 
characteristics, social involvement and service utilization from individuals w ith 
schizophrenia only. Among individuals w ith schizophrenia, comorbid diabetes had a 
prevalence rate of 4.75%, which is much lower than has been previously reported. For 
example, Muhkerjee, Decina, Bocola, Saraceni & Scapicchio (1996) report a rate of 15.8% 
among an inpatient population in Italy, while Dixon et al. (2000) report rates of between 9 
and 15% among individuals in usual care. In the RAl-MH, diabetes is coded under 'Medical 
diagnosis relevant to patient’s status', and is intended to capture information on medical 
diseases that are relevant to the persons stay or to their self-care status. However, only 
conditions that are subject to active treatment are recorded in this section. It is possible 
that a diagnosis of diabetes, if  not currently subject to active treatment via medication, may 
be overlooked and thus not recorded leading to lower than expected prevalence. Also, no 
screening was performed to detect a diagnosis of diabetes beyond what was captured in 
the RAl-MH and thus many individuals may have diabetes that is undetected (Cohen et al., 
2006).
Personal Characteristics
A number of personal characteristics were found to be more prevalent among 
persons w ith a comorbid diagnosis of diabetes. Persons with comorbid diabetes, as 
compared to persons w ithout diabetes, were more often female, which is consistent w ith 
previous findings among individuals w ith schizophrenia (Dixon et al., 2000; Narayan,
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Boyle, Thompson, Sorensen, & Williamson, 2003). Individuals in the diabetes group were 
more likely to be over the age of 35, which is also consistent w ith the later onset of type 2 
diabetes (Koopman, Mainous, Diaz, & Geesey, 2005). Individuals with diabetes were 
significantly more likely to have a BMl in the overweight/or obese category (based on WHO 
(2006b) recommendations for the classification of BMl). Although individuals with 
schizophrenia or diabetes alone are at an increased risk for being overweight/obese, the 
compounding effects of the co-morbid conditions, through lifestyle and clinical symptoms, 
may contribute to excess body weight and the increased rates of overweight/obesity 
(Goodin, 2001; Schienkiewitz, Schulze, Hoffmann, Kroke, & Boeing, 2006). Care-planners 
should ensure that individuals with diabetes are receiving appropriate interventions to aid 
in weight loss as they are at greater risk for a number of poor outcomes, such as reduced 
physical and mental health quality of life (Dickerson et al., 2008) and poorer self-rated 
health status (Dixon et al., 2000).
In concordance w ith results of a study by Ascher-Scanum et al. (2007), individuals 
w ith diabetes were less likely to identify as being single. The reasons as to why individuals 
w ith the comorbid conditions are more likely to have a partner were not studied w ith in the 
contexts of this paper. However, women were over-represented among individuals w ith 
the co-morbid conditions and onset of schizophrenia generally occurs later among women, 
while symptoms among women with early onset schizophrenia are commonly less severe 
(Dickerson, 2007). The possibility of later onset or less severe symptoms of schizophrenia 
in early life among women may explain the increased rates of marriage and partnerships 
among individuals w ith comorbid diabetes. Furthermore, individuals w ith comorbid
59
diabetes were found to experience lower levels of psychosis (positive symptoms], which 
may allow them to function more easily in social settings or with a partner.
Unemployment rates among individuals w ith the comorbid conditions were 
significantly higher than among individuals w ithout diabetes, with nearly 95% of persons 
w ith diabetes being unemployed. A number of possible explanations exist which may 
explain the lower rates of employment, including the older age of the diabetes group, 
poorer cognitive functioning, impaired self-care and the higher number of medical 
comorbidities experienced by these individuals (Von Korff et al., 2005]. Persons w ith 
comorbid diabetes were more likely to have seen an occupational therapist, but were only 
equally as likely as individuals w ithout diabetes to have received vocational counseling. 
Future research should focus on whether increased rates of vocational counseling for 
individuals w ith schizophrenia and comorbid diabetes can help these individuals return to 
work.
It was somewhat surprising that individuals w ith diabetes had fewer years of formal 
education as type 2 diabetes does not generally onset until after the time when individuals 
would have completed their education (Koopman, Mainous, Diaz & Geesey, 2005]. The 
lower number of years of education may be associated with risk factors for diabetes, such 
as lower socio-economic status, smoking and a general unhealthy lifestyle, which are 
associated with fewer years of educational attainm ent (Robbins, Vaccarino, Zhang, & Kasl 
2005]. Persons w ith diabetes were less likely to reside in a private home or apartment and 
were more likely to live in a group home/mental health residence/assisted living facility or
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long-term care facility. This may be due to the older age of individuals with diabetes and 
their need for care w ith daily activities.
Functional Characteristics
Individuals w ith diabetes were more likely to score higher (poorer functioning) on 
the Cognitive Performance Scale (CPS). Literature on the association of diabetes and 
cognitive functioning suggests a link between poorer overall cognitive functioning and a 
diagnosis of diabetes (Cukierman, Gerstein, & Williamson, 2005). It has also been 
suggested that comorbid conditions, insulin resistance, and hyper/hypoglycaemia play a 
role in deleterious scores on cognitive functioning in individuals w ith diabetes (Kodl, & 
Seaquist, 2008). Research suggests that maintaining tight control over blood glucose 
levels and insulin levels, through diet, exercise and pharmacological interventions, can 
improve cognitive functioning in individuals w ith type 2 diabetes (Ryan et al., 2006).
Lower cognitive performance has been linked to impairments in physical 
functioning such as activities of daily living or instrumental activities of daily living so it  is 
not surprising that the comorbid group had greater levels of dependence on the Activities 
of Daily Living Hierarchy Scale and the Instrumental Activities of Daily Living Summary 
Index (Rosano et al., 2005). Reduced functioning on these scales may also be attributed to 
greater amounts of medical comorbidities, such as cardiopulmonary or musculoskeletal 
disorders which can reduce functioning and are more prevalent in individuals with 
diabetes (Wray, Ofstedal, Langa, & Blaum, 2005). Addressing medical comorbidities, 
through treatment and prevention strategies may aid in both the cognitive and physical 
functioning of individuals with diabetes.
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Clinical Characteristics
M ental Health Of the mental health characteristics examined, only measures on the
Positive Symptom Scale differed between individuals with and w ithout diabetes.
Individuals w ith diabetes experienced fewer positive symptoms in the days prior to 
assessment. Schultz, Miller, Oliver, Arndt, Flaum and Andreasen, (1997) found that age was 
negatively associated w ith severity of positive symptoms but not associated w ith severity 
of negative symptoms. The older age of individuals w ith diabetes and schizophrenia may 
explain the difference in positive symptoms compared to those w ith schizophrenia alone, 
who tend to be significantly younger. Future analyses that consider the role of age in this 
relationship are needed.
Physical Health In the 3 days prior to assessment, individuals w ith diabetes were
more likely to experience a number of health problems such as shortness of breath, chest 
pain, blurred vision and vision problems, skin or foot problems and frequent urination. 
Many of these symptoms may be attributed to diabetes itself, and are common among 
individuals w ith diabetes alone in the general population (Clark, Fox, & Grandy, 2007). 
Along w ith signs and symptoms of physical health problems, individuals w ith diabetes 
were more likely to have a diagnosed cardiopulmonary, musculoskeletal, neurological, 
gastrointestinal or other medical condition. This is consistent with the PORT study 
conducted by Dixon et al. (2000) and Ascher-Svanum et al. (2007) who found individuals 
w ith diabetes had a greater number of health conditions than did individuals w ith 
schizophrenia alone. These conditions are largely attributable to the disease course of 
diabetes, which can contribute to both microvascular and macrovascular diseases that
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include the above-mentioned conditions and may in turn contribute to the signs and 
symptoms of health problems (WHO, n.d.). The presence of any medical comorbidity has 
an impact on the quality of life of individuals w ith diabetes in the general population, and 
when multiple complications are present, quality of life is impacted even further (Coffey et 
al., 2002; Koopmanschap, 2002). The rate of medical comorbidities is significantly higher 
among individuals with diabetes, with 46.03% having at least one medical diagnosis other 
than diabetes, while only 17.38% of individuals w ith schizophrenia had one or more 
medical diagnosis. Although it is not feasible to suggest the reduction of medical 
comorbidities after they occur, proper treatment and care upon admission may aid in 
reducing further complications. It is encouraging to note that individuals w ith the 
comorbid conditions were more likely to see a nurse practitioner or MD (other than 
psychiatrist) in the 7 days prior to assessment, which may be an indication that their 
physical health status, including diabetes, is being monitored. Preventive measures should 
be further investigated among this population as research suggests that early detection of 
diabetes is highly treatable, even reversible, and significantly reduces the chances of 
developing medical complications (De Hert et al., 2006).
Individuals with diabetes were more likely than individuals without diabetes to 
exhibit signs of decreased motor activity in the form of slow shuffling gait. Diabetes has 
been previously associated w ith gait disturbances in the general population and has been 
associated w ith other symptoms of diabetes such as issues with feet and ankles as well as 
neuropathy (Arvanitakis, 2004; Mueller, Minor, Sahrmann, Schaff & Strube, 1994). 
Individuals who exhibit signs of gait disturbance are more likely to injure themselves while 
performing simple tasks such as walking, standing and sitting (Mueller, Minor, Sahrmann,
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Schaff & Strube, 1994). Again, preventing, addressing and treating symptoms of diabetes 
may aid in reducing the possibility of injury and also the autonomy of individuals in 
performing ADLs and I ADLs by reducing the incidence of decreased motor activity among 
individuals w ith diabetes.
Krein, Heisler, Piette, Makki and Kerr (2005) found that nearly 60% of individuals 
w ith diabetes report chronic pain. Although the present study found lower rates of pain 
(approximately 19.5%), individuals with diabetes experienced pain more 
frequently/severely than did individuals without diabetes. Experiencing pain is associated 
w ith poorer self-management of diabetes, difficulty following an exercise routine and 
eating plan, all of which contributes to increased risk of developing diabetic complications 
(Krein et al., 2005). The comorbid group was also less likely to have performed physical 
activity in the days prior to assessment. It is encouraging to note, however, that individuals 
w ith diabetes were more likely to have received pain management and more days of 
contact with a recreation therapist and dietician since admission. These intervention 
strategies may aid in reducing the effects of pain on diabetes self-management, increase the 
amount of time performing physical activity and aid individuals in eating a healthy, 
balanced diet leading to a lower chance of individuals developing health complications.
Social Characteristics/ Involvement
In this study, the family and/or friends of persons with diabetes were less likely to 
feel overwhelmed by the patient's illness. This is somewhat surprising given the extra care 
required by individuals with diabetes, as patients w ith diabetes also identify as requiring 
supervision w ith personal safety and support with ADLs and lADLs. The question.
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however, refers to the patient’s 'illness', which may have been taken to refer to 
schizophrenia rather than diabetes. Individuals with the comorbid conditions tend to have 
fewer positive symptoms, which may translate into easier interactions with the individual.
Service Utilization History (Past and Present)
Individuals with comorbid diabetes were older than those without diabetes during 
their first overnight hospitalization in a psychiatric unit but experienced more lifetime 
psychiatric admissions and were admitted for more time in the past 2 years compared to 
persons w ithout diabetes. However, they generally experienced longer times between 
admissions than did people w ithout diabetes. Although no data was available on the 
reason for each previous admission, it is somewhat surprising that individuals with 
diabetes would have a greater number of psychiatric admissions, as they appear to 
experience less severe symptoms of schizophrenia, which may explain the longer times 
between admissions. As individuals w ith diabetes were older and experienced more 
medical complications, the likelihood of an individual in this group being hospitalized is 
independently increased. This group did, however, experience more cognitive 
impairments and reduced ability to perform self-care skills which may impact their ability 
to care for themselves in the community, even w ith only mild mental health symptoms.
Individuals w ith diabetes were more likely to have had recent contact w ith 
community mental health. This may be a by-product of having a partner and more 
extensive social network that could remind them of scheduled meetings w ith community 
mental health workers. It may also stem from the increased comorbidity and complexity of 
their illness, which may require additional follow-up.
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The focus of interventions for individuals w ith the comorbid conditions differed in 
three domains. Individuals w ith diabetes were less likely to have received detoxification, 
behavioural management and were more likely to have received pain management. This 
suggests that individuals w ith diabetes and schizophrenia are less likely to experience or 
be admitted for problems concerning drugs or alcohol as compared to individuals w ith 
schizophrenia only. Although scores on the aggressive behaviour scale (ABS) showed no 
significant difference, reasons for the increased number of interventions in this domain 
among individuals w ith schizophrenia may be due to increased severity of psychotic 
symptoms and validated by the increased use of antipsychotics as acute control measures 
among individuals w ith schizophrenia only. Differences in the administration of pain 
management have been previously addressed.
As discussed earlier, seeing a nurse practitioner or MD was significantly associated 
w ith membership in the comorbid group; Ascher-Svanum et al. (2007) reported similar 
findings. This is most likely attributed to either the diagnosis of diabetes itself or w ith 
complications (i.e. cardiopulmonary, neurological or other conditions) arising from a 
diagnosis of diabetes.
Quality of Life
In the RAl-MH only one measure of subjective quality of life is incorporated and 
consists of the individual’s self-rated health. Individuals w ith diabetes were found to be 1.6 
times more likely to rate their own health as being poor compared to individuals w ithout 
diabetes, even after controlling for possible confounding variables. The findings here are 
consistent w ith the small amount of research that has been conducted on quality of life in
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individuals w ith comorbid diabetes and schizophrenia, and more specifically self-rated 
health (Dixon et al., 2000).
Previous research also suggests that rating physical health status as poor is linked to 
greater amounts of medical comorbidities (Ascher-Svanum et al., 2007; Dixon et al., 2000). 
This is in agreement with the present results that found that individuals w ith diabetes were 
more likely have cardiopulmonary, neurological, musculoskeletal, gastrointestinal and 
other medical diagnosis. Individuals with diabetes were also more likely to report a 
number of physical health problems upon admission including: shortness of breath, chest 
pain, difficulty or frequent urination, edema and skin or foot problems, all of which may 
contribute to lower self-rated health.
Addressing issues related to physical health status upon admission should be 
considered a prio rity  for individuals w ith comorbid diabetes. Women are more likely to 
have diabetes among this population and research has shown that women w ith diabetes 
are more likely to report a greater burden of illness and lower treatment satisfaction 
(Rubin & Peyrot, 1998). Every effort should be made to address potential physical health 
problems to maintain a high-level of treatment satisfaction, in regards to both an 
individuals psychiatric diagnosis as well as other medical conditions, for all individuals, 
especially women, in an effort to increase their perceived health status and quality of life.
When examining objective measures of quality of life, initia lly three measures were 
significant in the bivariate analysis. However, after controlling for possible confounders, 
the impact of diabetes on whether an individual had received a visit in the last 30 days 
from a long-standing social relation or family member lost significance. Two objective
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quality of life indicators remained significant after adjusting for potentially biasing 
variables. Individuals w ith diabetes were more likely to report having a confidant and 
were nearly three times as likely to be unemployed compared to individuals w ith 
schizophrenia only.
Individuals w ith diabetes may be more likely to report having a confidant, as they 
are also more likely to identify as being married or having a partner, an individual who may 
act as a confidant. Rosenfeld and Wenzel (1997) found that whether an individual reports 
having a confidant or not, as well as the strength of their social relationships has a 
significant impact on the quality of life of individuals w ith serious mental illness. In this 
respect, it  appears that individuals w ith diabetes, through reasons that are largely 
unknown, are more likely to have someone w ithin their social network who they consider a 
confidant and thus an increased sense of quality of life relative to this measure of social 
relationships. As no global scale of quality of life was available in the RAl-MH, it is 
impossible to tell the relative contribution of having a confidant to overall measures of 
quality of life.
It is not surprising that individuals w ith diabetes experience significantly higher 
rates of unemployment given that previous studies have shown that, among the general 
population, individuals w ith diabetes are more likely to be unemployed or experience 
greater amounts of lost productive time when employed (Stewart, Ricci, Ghee, Hirsch, & 
Brandenburg, 2007). Individuals who exhibit common symptoms of diabetes are more 
likely to report unemployment status than those w ith diabetes w ithout symptoms (Stewart 
et al., 2007). As diabetes is significantly associated w ith greater numbers of physical health
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problems in this population, the association w ith unemployment seems very plausible. 
However, the association between unemployment and an individual having both diabetes 
and schizophrenia is particularly strong. As symptoms of diabetes may be exacerbated by a 
diagnosis of schizophrenia, the possibility exists that a compounding effect exists in 
individuals w ith the comorbid conditions as both diabetes and schizophrenia are 
independently associated with greater risks of unemployment among the general 
population [Ho et al., 1998; Stewart et al., 2007].
Gainful employment has been associated w ith increased quality of life among 
individuals w ith diabetes and also among individuals with schizophrenia [Ho et al., 1998; 
Wexler et al., 2006]. Individuals with diabetes were more likely to have had contact w ith 
an occupational therapist since admission; however, the actual difference between those 
w ith and w ithout diabetes was small and neither group received much contact w ith an 
occupational therapist. As has been previously discussed, individuals with comorbid 
diabetes, compared to individuals with no diabetes, were only equally as likely to have 
received vocational rehabilitation although the staggeringly high rates of unemployment 
among this group suggests they are more in need of vocational interventions. Given the 
association of unemployment with detriments to quality of life, individuals w ith diabetes 
should be considered priority candidates for occupational therapy and vocational 
rehabilitation upon successful stabilization of symptoms related to admission.
Limitations
There are several limitations to this research study. Similar to many previous 
studies [Asher-Svanum et al., 2007; Dixon et al., 2000] a diagnosis of diabetes was
69
ascertained through medical records or self-report. No further testing was conducted to 
determine whether an individual had diabetes or not. As such a low prevalence rate of 
diabetes was observed in this population, individuals with undiagnosed diabetes may have 
been incorporated into the ‘no diabetes’ or schizophrenia only group, thus biasing the 
comparison results. Further, due to the nature of the coding for diabetes w ith in the RAI- 
MH, w ith only conditions subject to current active treatment or that are relevant to the 
patients stay being coded, only diabetes of the more severe forms may have been coded. 
This would reduce the power of the diabetes group, as it may not be representative of the 
true population of individuals with diabetes receiving inpatient care, rather it  may be 
representative of individuals with more severe forms of diabetes.
A great interest in the possible effects of second-generation anti-psychotics on the 
development of diabetes has been aroused since their widespread use began in the 1990's 
[Bushe & Leonard, 2004; Citrome et al., 2004). Although a medication section is present 
w ith in the RAI-MH, its use was not mandated upon initial implementation of the 
instrument in 2005. As such, no investigation of the association of second-generation anti- 
psychotics w ith in this inpatient population was possible.
In the present research study, no comparison was completed between the general 
psychiatric population or individuals w ith diabetes and no mental illness. As such, it  is 
im possible to determ ine w hether the findings are unique to individuals w ith d iabetes and 
schizophrenia. It is also impossible to determine the relative impact of diabetes among 
individuals w ith schizophrenia, compared to diabetes in combination with other mental 
illnesses. Although the inclusion of a control group [schizophrenia only) is a significant
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advantage over previous findings, future studies should include a group of individuals with 
diabetes only and w ith diabetes among the general psychiatric population.
Although the RAI-MH provides a substantial amount of information that is useful in 
care planning, quality improvement and many other domains of health care support, the 
present study was limited by the information contained within the instrument. Examining 
quality of life among individuals w ith comorbid schizophrenia and diabetes was identified 
as an objective of the present study; however, few measures of quality of life are present 
w ith in the instrument and none have been validated for use as quality of life indicators. 
That said, there are measures w ithin the RAI-MH that are strikingly similar to measures 
that have been identified previously [Hofer et al., 2004; Watson, Clark and Tellegan, 1988] 
as indicators of quality of life. It would be pertinent to investigate the development of a 
valid and reliable quality of life scale based on the inclusion of items w ith in the RAI-MH.
The RAI-MH also did not include information on age of diagnosis, for either 
schizophrenia or diabetes. As length of time since diagnosis for either condition may affect 
both severity of symptoms and probability of complications, knowing the age of onset 
would be useful in establishing length of time w ith the respective disease. Knowing the 
age at onset for both diseases would allow for the investigation of time course; whether a 
diagnosis of diabetes preceded a diagnosis of schizophrenia or vice versa among this 
population.
Although no service utilization costs were analyzed in this study due to a lack of 
data available in the RAI-MH, Dixon et al. [2000) report that service utilization costs were 
significantly higher among individuals w ith co-occurring diabetes and schizophrenia. It is
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conceivable that health care costs associated w ith diabetes among this group would also be 
considerably higher due to the number of lifetime hospitalizations, the length of time 
hospitalized, and treatment of medical complications while hospitalized. Future studies 
should focus on determining the service utilization costs and means to address disparities 
in these costs among individuals with schizophrenia and co-morbid diabetes, as the costs 
would appear to be significantly higher.
The present research has identified many personal factors, clinical and functional 
characteristics, areas of social involvement and service utilization history in which 
individuals w ith schizophrenia and comorbid diabetes differ from individuals w ith 
schizophrenia only. It is possible, through the extensive number of variables examined that 
by chance a difference between groups was observed when in fact there was no difference. 
However, this should not significantly impact the many striking differences that have been 
identified through this study.
Implications fo r Public Health
The health of individuals is significantly compromised by a diagnosis of 
schizophrenia and is further impacted by a diagnosis of diabetes as has been demonstrated 
through the present research study. The prevalence rates of comorbid diabetes among 
individuals with schizophrenia are known to be two to five times higher than the general 
population; however, the current study found rates comparable to rates among the general 
population. Changes must occur in a number of core areas to ensure that the prevalence of 
diabetes is reduced in individuals with schizophrenia and that the quality of life is
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improved and the impact of a diagnosis of diabetes is lessened in individuals who do 
develop diabetes.
The Canadian Diabetes Association (CDA) (2003) has included schizophrenia as a 
risk factor for developing diabetes in its current clinical practice. The website of the CDA 
has sections specifically devoted to understanding and managing diabetes for Aboriginal 
individuals (CDA, 2008); however, no information is targeted to individuals w ith mental 
illness, a group afflicted w ith similarly high rates of diabetes. An increase in resources, for 
individuals w ith mental illness, and more specifically schizophrenia, should be 
investigated. For instance, a section devoted to individuals with mental illness on the CDA 
website may aid in calling attention to the increased risk, the unique risk factors, methods 
for managing these risk factors, and resources (i.e. support groups, exercise classes, 
dieticians) available to individuals w ith mental illness.
The rates of under-detection of diabetes in individuals w ith schizophrenia are 
extremely high (Voruganti et al., 2007). The present study suggests rates of less than 5%, 
while some studies suggest rates of up to 19% among individuals with schizophrenia 
(Mukherjee et al., 1996; Subramaniam, Chong & Pek, 2003). The identification of pre­
diabetes, or heightened risk for the development of diabetes is crucial in this population as 
full diabetes may be preventable, or even reversible (De Hert et al., 2006). Screening for 
diabetes and pre-diabetes should therefore be a priority  among individuals w ith 
schizophrenia. Educating physicians and clinicians about the increased risk for diabetes 
and the potential benefits to screening is thus highly recommended.
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Future research needs to be done in a number of areas to determine the best ways 
in which diabetes can be prevented and managed in this population. For instance, the 
reasons as to why individuals with diabetes experience more hospitalizations with longer 
stays may reveal areas in which care planners could focus their efforts to reduce the 
burden of comorbid diabetes among individuals w ith schizophrenia. Second, conventional 
interventions for diabetes do not necessarily meet the needs of individuals w ith mental 
illness. A number of studies suggest that diabetes can be prevented or delayed for 
individuals in the general population in the pre-diabetes state by making lifestyle 
interventions in combination with pharmacotherapy, such as metformin or insulin 
resistance inhibitors (Padwal, Majumdar, Johnson, Varney & McAlister, 2005;Yamaoka & 
Tango, 2005); however, research is only now beginning on methods for preventing the 
progression to diabetes in individuals w ith schizophrenia.
The Diabetes Prevention Program in Schizophrenia (n.d.), a program being 
investigated through a five-year prospective, controlled tria l sponsored in part by Hamilton 
Health Sciences and McMaster Univerity, seeks to extend current diabetes prevention 
strategies to meet the needs of individuals w ith schizophrenia. The program includes 
early interventions such as healthy eating habits, regular moderate exercise and 
pharmacotherapy targeted to individuals w ith schizophrenia who are in the pre-diabetes 
stage and at high risk for developing frank diabetes. The aim of the program is to impact 
modifiable risk factors in an effort to reduce overall incidence of diabetes. As individuals 
w ith the comorbid conditions suffer from poorer overall outcomes and poorer self-rated 
health, targeting diabetes before full onset would appear to be the most effective way in 
improving outcomes for individuals w ith schizophrenia who are at risk for developing
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diabetes. The results of the Diabetes Prevention Program in Schizophrenia, in combination 
w ith further research, may indicate the most effective intervention methods for reducing 
incidence of diabetes among persons w ith schizophrenia.
Conclusion
Overall, individuals with comorbid diabetes and schizophrenia share many 
common characteristics of individuals with diabetes among the general population. Care- 
planners for persons w ith diabetes entering a mental health facility/bed should ensure that 
normal practices for managing diabetes among the general population are not over looked 
during treatment of their psychiatric diagnosis. Practices such as close monitoring of the 
individuals blood glucose levels, ensuring they are getting ample amounts of exercise, are 
eating a healthy balanced diet, pain management techniques are being implemented and 
ensuring that any complications are being closely monitored to ensure the severity of the 
physical health problems do not worsen are all extremely important in managing diabetes. 
Individuals w ith diabetes should also be seen by a physician regularly while being treated, 
see an occupational and recreation therapist and be offered vocational rehabilitation to 
guide the individual in engaging in meaningful activities such as employment and physical 
activity. In combination, these recommendations w ill aid in improving the quality of life of 
individuals living w ith schizophrenia and co-morbid diabetes. Care planners should be 
particularly a ttentive to the needs of individuals w ith schizophrenia entering a psychiatric 
facility or mental health bed who have a diagnosis of diabetes as the comorbid conditions 
may have a cumulative effect which may compound the effects of diabetes w ith those of 
schizophrenia.
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Beyond monitoring individuals who initia lly identify with diabetes, a movement 
towards intensive screening for diabetes among individuals w ith schizophrenia must be 
made due to the overwhelming amount of literature which suggests a link between 
diabetes and schizophrenia which may lead to the substantially increased rates of diabetes 
among individuals with schizophrenia. Early detection of diabetes is essential to proper 
treatment and may help to reduce the many disparities identified in the present study, 
especially concerning the high number of co-morbid conditions and lower subjective and 
objective quality of life experienced by individuals with comorbid diabetes.
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